

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> :C12N 15/00, 15/13, 15/62  
C07K 13/00, G01N 33/531, 33/68

A1

(11) International Publication Number:

WO 93/19172

(43) International Publication Date:

30 September 1993 (30.09.93)

(21) International Application Number: PCT/GB93/00605

(22) International Filing Date: 24 March 1993 (24.03.93)

(30) Priority data:

9206318.9 24 March 1992 (24.03.92) GB  
PCT/GB92/00883 15 May 1992 (15.05.92) WO(34) Countries for which the regional  
or international application  
was filed:

GB et al.

(71) Applicants (for all designated States except US): CAM-  
BRIDGE ANTIBODY TECHNOLOGY LIMITED  
[GB/GB]; The Science Park, Melbourn, Cambridgeshire  
SG8 6EJ (GB). MEDICAL RESEARCH COUNCIL  
[GB/GB]; 20 Park Crescent, London WIN 4AL (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JOHNSON, Kevin, Stu-  
art [GB/GB]; 181 Huntingdon Road, Cambridge CB3  
ODH (GB). WINTER, Gregory, Paul [GB/GB]; 64 Cav-  
endish Avenue, Cambridge CB1 4UT (GB). GRIF-  
FITHS, Andrew, David [GB/GB]; 28 Lilac Court, Cher-  
ry Hinton Road, Cambridge CB1 4AY (GB). SMITH,  
Andrew, John, Hammond [GB/GB]; 82 Devonshire  
Mews, Devonshire Road, Cambridge CB2 2BI (GB).  
WATERHOUSE, Peter [AU/AU]; 5 Bangle Street, O  
Connor, Canberra, ACT 2601 (AU).(74) Agent: ARMITAGE, Ian, Michael; Mewburn Ellis, 2 Cur-  
sitor Street, London EC4A 1BQ (GB).(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ,  
DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG,  
MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK,  
UA, US, European patent (AT, BE, CH, DE, DK, ES,  
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI pa-  
tent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,  
SN, TD, TG).

Published

With international search report.


Before the expiration of the time limit for amending the  
claims and to be republished in the event of the receipt of  
amendments.

(54) Title: METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS

(57) Abstract

Methods, recombinant host cells and kits are disclosed for the production of members of specific binding pairs (sbp), e.g. antibodies, using display on the surface of secreted replicable genetic display packages (rgdps), e.g. filamentous phage. To produce a library of great diversity recombination occurs between first and second vectors comprising nucleic acid encoding first and second polypeptide chains of sbp members respectively, thereby producing recombinant vectors each encoding both a first and a second polypeptide chain component of an sbp member. The recombination may take place *in vitro* or intracellularly and may be site-specific, e.g. involving use of the *loxP* sequence and mutants thereof. Recombination may take place after prior screening or selecting for rgdps displaying sbp members which bind complementary sbp member of interest.

## Polycombinatorial libraries

Potential library size =  $10^{12}$ 

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria                  | FR | France                                | MR | Mauritania               |
| AU | Australia                | GA | Gabon                                 | MW | Malawi                   |
| BB | Barbados                 | GB | United Kingdom                        | NL | Netherlands              |
| BE | Belgium                  | GN | Guinea                                | NO | Norway                   |
| BF | Burkina Faso             | GR | Greece                                | NZ | New Zealand              |
| BG | Bulgaria                 | HU | Hungary                               | PL | Poland                   |
| BJ | Benin                    | IE | Ireland                               | PT | Portugal                 |
| BR | Brazil                   | IT | Italy                                 | RO | Romania                  |
| CA | Canada                   | JP | Japan                                 | RU | Russian Federation       |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CG | Congo                    | KR | Republic of Korea                     | SE | Sweden                   |
| CH | Switzerland              | KZ | Kazakhstan                            | SK | Slovak Republic          |
| CI | Côte d'Ivoire            | LJ | Liechtenstein                         | SN | Senegal                  |
| CM | Cameroon                 | LK | Sri Lanka                             | SU | Soviet Union             |
| CS | Czechoslovakia           | LU | Luxembourg                            | TD | Chad                     |
| CZ | Czech Republic           | MC | Monaco                                | TG | Togo                     |
| DE | Germany                  | MG | Madagascar                            | UA | Ukraine                  |
| DK | Denmark                  | ML | Mali                                  | US | United States of America |
| ES | Spain                    | MN | Mongolia                              | VN | Viet Nam                 |
| FI | Finland                  |    |                                       |    |                          |

METHODS FOR PRODUCING MEMBERS OF  
SPECIFIC BINDING PAIRS

The present invention relates to methods for producing members of specific binding pairs (sbp). In particular, the present invention relates to methods for producing members of specific binding pairs involving recombination between vectors which comprise nucleic acid encoding polypeptide chain components of sbp members.

Structurally, the simplest antibody (IgG) comprises four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulphide bonds (see figure 1). The light chains exist in two distinct forms called kappa (K) and lambda ( $\lambda$ ). Each chain has a constant region (C) and a variable region (V). Each chain is organized into a series of domains. The light chains have two domains, corresponding to the C region and the other to the V region. The heavy chains have four domains, one corresponding to the V region and three domains (1,2 and 3) in the C region. The antibody has two arms (each arm being a Fab region), each of which has a VL and a VH region associated with each other. It is this pair of V regions (VL and VH) that differ from one antibody to another (owing to amino acid sequence variations), and which together are responsible for recognising the antigen and providing an antigen binding site (ABS). In even more detail, each V region is made up from three complementarity determining regions (CDR) separated by four framework regions (FR). The CDR's are the most variable part of the variable regions, and they perform the critical antigen binding function. The CDR regions are derived from many potential germ line sequences via a complex process involving recombination, mutation and selection.

It has been shown that the function of binding

antigens can be performed by fragments of a whole antibody. Example binding fragments are (i) the Fab fragment consisting of the VL, VH, CL and CH1 domains; (ii) the Fd fragment consisting of the VH and CH1 domains; (iii) the Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (iv) the dAb fragment (Ward, E.S. et al., Nature 341, 544-546 (1989) which consists of a VH domain; (v) isolated CDR regions; and (vi) F(ab')<sub>2</sub> fragments, a bivalent fragment comprising two Fab fragments linked by a disulphide bridge at the hinge region.

Although the two domains of the Fv fragment are coded for by separate genes, it has proved possible to make a synthetic linker that enables them to be made as a single protein chain (known as single chain Fv (scFv); Bird, R.E. et al., Science 242, 423-426 (1988) Huston, J.S. et al., Proc. Natl. Acad. Sci., USA 85, 5879-5883 (1988)) by recombinant methods. These scFv fragments were assembled from genes from monoclonals that had been previously isolated.

Bacteriophage have been constructed that express and display at their surface a large biologically functional binding molecule (eg antibody fragments, and enzymes and receptors) and which remain intact and infectious. This is described in WO 92/01047, the disclosure of which is herein incorporated by reference. Readers of the present document are urged to consult WO 92/01047 for detailed explanation of many of the procedures used in the experiments described herein.

The applicants have called the structure which comprises a virus particle and a binding molecule displayed at the viral surface a 'package'. Where the binding molecule is an antibody, an antibody derivative or fragment, or a domain that is homologous to an immunoglobulin domain, the applicants call the package a 'phage antibody' (pAb). However, except where the context demands otherwise, where the term phage antibody is used

generally, it should also be interpreted as referring to any package comprising a virus particle and a biologically functional binding molecule displayed at the viral surface.

5 pAbs have a range of applications in selecting antibody genes encoding antigen binding activities. For example, pAbs could be used for the cloning and rescue of hybridomas (Orlandi, R., et al (1989) PNAS 86 p3833-3837), and in the screening of large combinatorial  
10 libraries (such as found in Huse, W.D. et al., 1989, Science 246, 1275-1281). In particular, rounds of selection using pAbs may help in rescuing the higher affinity antibodies from the latter libraries. It may be preferable to screen small libraries derived from  
15 antigen-selected cells (Casali, P., et al., (1986) Science 234 p476-479) to rescue the original VH/VL pairs comprising the Fv region of an antibody. The use of pAbs may also allow the construction of entirely synthetic antibodies. Furthermore, antibodies may be  
20 made which have some synthetic sequences e.g. CDRs, and some naturally derived sequences. For example, V-gene repertoires could be made in vitro by combining un-rearranged V genes, with D and J segments. Libraries of pAbs could then be selected by binding to antigen,  
25 hypermutated in vitro in the antigen-binding loops or V domain framework regions, and subjected to further rounds of selection and mutagenesis.

The demonstration that a functional antigen-binding domain can be displayed on the surface of phage,  
30 has implications beyond the construction of novel antibodies. For example, if other protein domains can be displayed at the surface of a phage, phage vectors could be used to clone and select genes by the binding properties of the displayed protein. Furthermore,  
35 variants of proteins, including epitope libraries built into the surface of the protein, could be made and readily selected for binding activities. In effect,

other protein architectures might serve as "nouvelle" antibodies.

The technique provides the possibility of building antibodies from first principles, taking advantage of the structural framework on which the antigen binding loops fold. In general, these loops have a limited number of conformations which generate a variety of binding sites by alternative loop combinations and by diverse side chains. Recent successes in modelling antigen binding sites augurs well for de novo design. In any case, a high resolution structure of the antigen is needed. However, the approach is attractive for making e.g. catalytic antibodies, particularly for small substrates. Here side chains or binding sites for prosthetic groups might be introduced, not only to bind selectively to the transition state of the substrate, but also to participate directly in bond making and breaking. The only question is whether the antibody architecture, specialised for binding, is the best starting point for building catalysts. Genuine enzyme architectures, such as the triose phosphate isomerase (TIM) barrel, might be more suitable. Like antibodies, TIM enzymes also have a framework structure (a barrel of  $\beta$ -strands and  $\alpha$ -helices) and loops to bind substrate. Many enzymes with a diversity of catalytic properties are based on this architecture and the loops might be manipulated independently on the frameworks for design of new catalytic and binding properties. The phage selection system as provided by the present disclosure can be used to select for antigen binding activities and the CDR loops thus selected, used on either an antibody framework or a TIM barrel framework. Loops placed on a e.g. a TIM barrel framework could be further modified by mutagenesis and subjected to further selection. Thus, there is no need to select for high affinity binding activities in a single step. The strategy of the immune

system, in which low affinity evolves to high affinity seems more realistic and can be mimicked using this invention.

One class of molecules that could be useful in this type of application are receptors. For example, a specific receptor could be displayed on the surface of the phage such that it would bind its ligand. The receptor could then be modified by, for example, in vitro mutagenesis and variants having higher binding affinity for the ligand selected. The selection may be carried out according to one or more of the formats described below.

Alternatively, the phage-receptor could be used as the basis of a rapid screening system for the binding of ligands, altered ligands, or potential drug candidates. The advantages of this system namely of simple cloning, convenient expression, standard reagents and easy handling makes the drug screening application particularly attractive. In the context of this discussion, receptor means a molecule that binds a specific, or group of specific, ligand(s). The natural receptor could be expressed on the surface of a population of cells, or it could be the extracellular domain of such a molecule (whether such a form exists naturally or not), or a soluble molecule performing a natural binding function in the plasma, or within a cell or organ.

Another possibility, is the display of an enzyme molecule or active site of an enzyme molecule on the surface of a phage (see examples 11,12,30,31,32 and 36 of WO 92/01047). Once the phage enzyme is expressed, it can be selected by affinity chromatography, for instance on columns derivatized with transition state analogues. If an enzyme with a different or modified specificity is desired, it may be possible to mutate an enzyme displayed as a fusion on bacteriophage and then select on a column derivatised with an analogue selected to

have a higher affinity for an enzyme with the desired modified specificity.

Although throughout this application, the applicants discuss the possibility of screening for higher affinity variants of pAbs, they recognise that in some applications, for example low affinity chromatography (Ohlson, S. et al Anal. Biochem. 169, p204-208 (1988)), it may be desirable to isolate lower affinity variants.

pAbs also allow the selection of antibodies for improved stability. It has been noted for many antibodies, that yield and stability are improved when the antibodies are expressed at 30°C rather than 37°C. If pAbs are displayed at 37°C, only those which are stable will be available for affinity selection. When antibodies are to be used in vivo for therapeutic or diagnostic purposes, increased stability would extend the half-life of antibodies in circulation.

Although stability is important for all antibodies and antibody domains selected using phage, it is particularly important for the selection of Fv fragments which are formed by the non-covalent association of VH and VL fragments. Fv fragments have a tendency to dissociate and have a much reduced half-life in circulation compared to whole antibodies. Fv fragments are displayed on the surface of phage, by the association of one chain expressed as a gene III protein fusion with the complementary chain expressed as a soluble fragment. If pairs of chains have a high tendency to dissociate, they will be much less likely to be selected as pAbs. Therefore, the population will be enriched for pairs which do associate stably. Although dissociation is less of a problem with Fab fragments, selection would also occur for Fab fragments which associate stably. pAbs allow selection for stability to protease attack, only those pAbs that are not cleaved by proteases will be capable of binding their ligand and



therefore populations of phage will be enriched for those displaying stable antibody domains.

The technique of displaying binding molecules on the phage surface can also be used as a primary cloning system. For example, a cDNA library can be constructed and inserted into the bacteriophage and this phage library screened for the ability to bind a ligand. The ligand/binding molecule combination could include any pair of molecules with an ability to specifically bind to one another e.g. receptor/ligand, enzyme/substrate (or analogue), nucleic acid binding protein/nucleic acid etc. If one member of the complementary pair is available, this may be a preferred way of isolating a clone for the other member of the pair.

The first functional antibody molecules to be expressed on the surface of filamentous phage were single-chain Fv's (scFv), so-called because heavy and light chain variable domains, normally on two separate proteins, are covalently joined by a flexible linker peptide. Alternative expression strategies have also been successful. Fab molecules can be displayed on phage if one of the chains (heavy or light) is fused to g3 capsid protein and the complementary chain exported to the periplasm as a soluble molecule. The two chains can be encoded on the same or on different replicons; the important point is that the two antibody chains in each fab molecule assemble post-translationally and the dimer is incorporated into the phage particle via linkage of one of the chains to g3p.

More recent cloning has been performed with 'phagemid' vectors which have ca. 100-fold higher transformation efficiencies than phage DNA. These are plasmids containing the intergenic region from filamentous phages which enables single-stranded copies of the phagemid DNA to be produced, and packaged into infectious filamentous particles when cells harbouring them are infected with 'helper' phages providing the

phage components in trans. When phagemids contain gIII fused to an antibody gene (eg PHEN-1), the resulting fusion protein is displayed on the phagemid particle (Hoogenboom, H. R., A. D. Griffiths, K. S. Johnson, D. J. Chiswell, P. Hudson and G. Winter. (1991). Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 19 (15), 4133-4137). Efficient strategies have been developed for cloning antibody genes, a factor which becomes most important when dealing with large numbers of different antibody fragments such as repertoires.

The cloning vector fd-DOG-1 was used in early work with phage antibody repertoires in which scFv fragments were derived from spleen mRNA of mice immunised with the hapten oxazalone (Clackson, T., H. R. Hoogenboom, A. D. Griffiths and G. Winter. (1991). Making antibody fragments using phage display libraries. Nature. 352 , 624-628.); VH and VL domains were separately amplified then linked at random via a short DNA fragment encoding the scFv linker peptide to produce a library of approximately  $10^5$  different clones. This was panned against the immunising antigen to select combinations of VH and VL which produced functional antibodies. Several binders were isolated, one in particular having an affinity not far below that of the best monoclonal antibodies produced by conventional hybridoma technology.

In a mouse, at any one time there are approximately  $10^7$  possible H chains and  $10^5$  possible L chains, making a total of  $10^{12}$  possible VH:VL combinations when the two chains are combined at random (these figures are estimates and simply provide a rough guide to repertoire size). By these figures, the above mouse library sampled only 1 in  $10^7$  of the possible VH:VL combinations. It is likely that good affinity antibodies were isolated in the work described in the preceeding

paragraph because the spleen cells derived from an immunised donor in which B cells capable of recognising the antigen are clonally expanded and producing large quantities of Ig mRNA. The low library complexity in  
5 this experiment is partly due to the intrinsically low transformation efficiency of phage DNA compared to plasmid (or phagemid).

Marks et al. (Marks, J.D., Hoogenboom, H.R., Bonnert, T.P., McCafferty, J., Griffiths, A.D. and  
10 Winter, G. (1991) By-passing immunization: Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581-597) and WO92/01047 describe construction of an antibody repertoire from unimmunised humans cloned in the phagemid PHEN-1. This library,  
15 consisting of  $3 \cdot 10^7$  clones has so far yielded specific antibodies to many different antigens. These antibodies tend to have the moderate affinities expected of a primary immune response, demonstrating that usable antibodies to a range of structurally diverse antigens  
20 can indeed be isolated from a single resource.

New binders can be created from clones isolated from phage antibody libraries using a procedure called 'chain-shuffling'. In this process one of the two chains is fixed and the other varied. For example, by fixing  
25 the heavy chain from the highest affinity mouse anti-OX phage antibody and recloning the repertoire of light chains alongside it, libraries of  $4 \cdot 10^7$  were constructed. Several new OX-binders were isolated, and the majority of these had light chains that were distinct from those  
30 first isolated and considerably more diverse. These observations reflect the fact that a small library is sufficient to tap the available diversity when only one chain is varied, a useful procedure if the original library was not sufficiently large to contain the  
35 available diversity.

The size of the library is of critical importance. This is especially true when attempting to

isolate antibodies from a naive human repertoire, but is equally relevant to isolation of the highest affinity antibodies from an immunised source.

It is clear that while phage display is an  
5 exceptionally powerful tool for cloning and selecting  
antibody genes, we are tapping only the tiniest fraction  
of the potential diversity using existing technology.  
Transformation efficiencies place the greatest  
limitation on library size with  $10^9$  being about the limit  
10 using current methods. Rough calculations suggest that  
this is several orders of magnitude below the target  
efficiency; more rigorous analysis confirms it.

Perelson and Oster have given theoretical  
consideration to the relationship between size of the  
15 immune repertoire and the likelihood of generating an  
antibody capable recognising a given epitope with  
greater than a certain threshold affinity,  $K$ . The  
relationship is described by the equation:

$$P = e^{-N(p[K])}$$

20 Where  $P$  = probability that an epitope is not  
recognised with an affinity above the threshold value  $K$   
by any antibody in the repertoire,

$N$  = number of different antibodies in the  
repertoire, and

25  $p[K]$  = probability that an individual antibody  
recognises a random epitope with an affinity above the  
threshold value  $K$

In this analysis  $p[K]$  is inversely proportional  
30 to affinity, although an algorithm describing this  
relationship precisely has not been deduced. Despite  
this, it is apparent that the higher the affinity of the  
antibody, the lower its  $p[K]$  and the larger the  
repertoire needs to be to achieve a reasonable  
35 probability of isolating that antibody. The other  
important feature is that the function is exponential;

as shown in fig 1, a small change in library size can have either a negligible or a dramatic effect on the probability of isolating an antibody with a given  $p[K]$  value, depending upon what point on the curve is given by the library size.

WO 92/01047 and WO92/20791 describe how the limitations of transformation efficiency (and therefore the upper limit on library size) can be overcome by use of other methods for introducing DNA into cells, such as infection. In one configuration, heavy and light chain genes are cloned separately on two different replicons, at least one of which is capable of being incorporated into a filamentous particle. Infectious particles carrying one chain are infected into cells harbouring the complementary chain; infection frequencies of  $>90\%$  can be readily achieved. Heavy and light chains are then able to associate post-translationally in the periplasm and the combination displayed on the surface of the filamentous particle by virtue of one or both chains being connected to g3p. For example, a library of  $10^7$  heavy chains is cloned as an unfused population in a phagemid, and  $10^7$  light chains are cloned as g3 fusions in fd-DOG-1. Both populations are then expanded by growth such that there are  $10^7$  of each heavy chain-containing cell and  $10^7$  copies of each light chain phage. By allowing the phage to infect the cells,  $10^7 \times 10^7 = 10^{14}$  unique combinations can be created, because there are  $10^7$  cells carrying the same heavy chain which can each be infected by  $10^7$  phage carrying different light chains. When this is repeated for each different heavy chain clone then one ends up with up to  $10^{14}$  different heavy/light combinations in different cells. This strategy is outlined in fig 2, which shows the heavy chain cloned as g3 fusions on phage and the light chains expressed as soluble fragments from a phagemid. Clearly, the reverse combination, light chains on phage, heavy chain on phagemid, is also tenable.

In the configuration shown in fig 2, fd-DOG 'rescues' the phagemid so that both phage and phagemid DNA is packaged into filamentous particles, and both types will have paired heavy and light chains on their surface, despite having the genetic information for only one of them. For a given antigen or epitope, the vast majority of the heavy and light chain pairings will be non-functional (ie. will not bind that antigen or epitope), so that selection on antigen will have the effect of vastly reducing the complexity of the heavy and light chain populations. After the first round of selection the clones are re-assorted, for example by infecting fresh host cells and selecting for both replicons. After several rounds of antigen selection and recovery of the two replicons, the considerably reduced heavy and light chain populations can be cloned onto the same replicon and analysed by conventional means. Selection from the, say,  $10^{14}$  combinations produces a population of phages displaying a particular combination of H and L chains having the desired specificity. The phages selected however, will only contain DNA encoding one partner of the paired H and L chains. Selection for the two replicons may be as follows. Vectors of the H chain library may encode tetracycline resistance, with vectors of the L chain library encoding ampicillin resistance. The sample elute containing the population is divided into two portions. A first portion is grown on e.g. tetracycline plates to select those bacteriophage containing DNA encoding H chains which are involved in the desired antigen binding. A second portion is grown on e.g. ampicillin plates to select those bacteriophage containing phagemid DNA encoding L chains which are involved in the desired antigen binding. A set of colonies from individually isolated clones e.g. from the tetracycline plates are then used to infect specific colonies e.g. from the ampicillin plates. This results in bacteriophage expressing

specific combinations of H and L chains which can then be assayed for antigen binding.

One technical problem with the use of separate replicons for VL and VH chains is so-called

- 5 'interference' between filamentous phage origins of replication carried on different replicons as a result of competition for the same replication machinery.

- Procedures have been described which work on the principle of first reducing the complexity of a  
10 repertoire then recloning one or both chains of the reduced population (W092/20791). The present invention provides a different approach.

#### TERMINOLOGY

- Much of the terminology discussed in this section  
15 has been mentioned in the text where appropriate.

#### Specific Binding Pair (sbp)

- This describes a pair of molecules (each being a member of a specific binding pair) which are naturally derived or synthetically produced. One of the pair of  
20 molecules, has an area on its surface, or a cavity which specifically binds to, and is therefore defined as complementary with a particular spatial and polar organisation of the other molecule, so that the pair have the property of binding specifically to each other.  
25 Examples of types of specific binding pairs are antigen-antibody, biotin-avidin, hormone-hormone receptor, receptor-ligand, enzyme-substrate, IgG-protein A.

#### Multimeric Member

- This describes a first polypeptide which will  
30 associate with at least a second polypeptide, when the polypeptides are expressed in free form and/or on the surface of a substrate. The substrate may be provided by a bacteriophage. Where there are two associated polypeptides, the associated polypeptide complex is a  
35 dimer, where there are three, a trimer etc. The dimer, trimer, multimer etc or the multimeric member may comprise a member of a specific binding pair.

Example multimeric members are heavy domains based on an immunoglobulin molecule, light domains based on an immunoglobulin molecule, T-cell receptor subunits.

Replicable Genetic Display Package (Rgdp)

5           This describes a biological particle which has genetic information providing the particle with the ability to replicate. The particle can display on its surface at least part of a polypeptide. The polypeptide can be encoded by genetic information native to the

10           particle and/or artificially placed into the particle or an ancestor of it. The displayed polypeptide may be any member of a specific binding pair eg. heavy or light chain domains based on an immunoglobulin molecule, an enzyme or a receptor etc.

15           The particle may be a virus eg. a bacteriophage such as fd or M13.

Package

          This describes a replicable genetic display package in which the particle is displaying a member of

20           a specific binding pair at its surface. The package may be a bacteriophage which displays an antigen binding domain at its surface. This type of package has been called a phage antibody (pAb).

Antibody

25           This describes an immunoglobulin whether natural or partly or wholly synthetically produced. The term also covers any protein having a binding domain which is homologous to an immunoglobulin binding domain. These proteins can be derived from natural sources, or partly

30           or wholly synthetically produced.

          Example antibodies are the immunoglobulin isotypes and the Fab, F(ab<sup>1</sup>)<sub>2</sub>, scFv, Fv, dAb, Fd fragments.

Immunoglobulin Superfamily

35           This describes a family of polypeptides, the members of which have at least one domain with a structure related to that of the variable or constant



domain of immunoglobulin molecules. The domain contains two  $\beta$ -sheets and usually a conserved disulphide bond (see A.F. Williams and A.N. Barclay 1988 Ann. Rev Immunol. 6 381-405).

Example members of an immunoglobulin superfamily are CD4, platelet derived growth factor receptor (PDGFR), intercellular adhesion molecule. (ICAM). Except where the context otherwise dictates, reference to immunoglobulins and immunoglobulin homologs in this application includes members of the immunoglobulin superfamily and homologs thereof.

#### Homologs

This term indicates polypeptides having the same or conserved residues at a corresponding position in their primary, secondary or tertiary structure. The term also extends to two or more nucleotide sequences encoding the homologous polypeptides.

Example homologous peptides are the immunoglobulin isotypes.

#### Functional

In relation to a sbp member displayed on the surface of a rgdp, means that the sbp member is presented in a folded form in which its specific binding domain for its complementary sbp member is the same or closely analogous to its native configuration, whereby it exhibits similar specificity with respect to the complementary sbp member. In this respect, it differs from the peptides of Smith et al, supra, which do not have a definite folded configuration and can assume a variety of configurations determined by the complementary members with which they may be contacted.

#### Genetically diverse population

In connection with sbp members or polypeptide components thereof, this is referring not only to diversity that can exist in the natural population of cells or organisms, but also diversity that can be

created by artificial mutation in vitro or in vivo.

Mutation in vitro may for example, involve random mutagenesis using oligonucleotides having random mutations of the sequence desired to be varied. In vivo mutagenesis may for example, use mutator strains of host microorganisms to harbour the DNA (see Example 38 of WO 92/01047). The word "population" itself may be used to denote a plurality of e.g. polypeptide chains, which are not genetically diverse i.e. they are all the same.

10 Domain

A domain is a part of a protein that is folded within itself and independently of other parts of the same protein and independently of a complementary binding member.

15 Folded Unit

This is a specific combination of an  $\alpha$ -helix and/or  $\beta$ -strand and/or  $\beta$ -turn structure. Domains and folded units contain structures that bring together amino acids that are not adjacent in the primary structure.

20 Free Form

This describes the state of a polypeptide which is not displayed by a replicable genetic display package.

25 Conditionally Defective

This describes a gene which does not express a particular polypeptide under one set of conditions, but expresses it under another set of conditions. An example, is a gene containing an amber mutation expressed in non-suppressing or suppressing hosts respectively.

Alternatively, a gene may express a protein which is defective under one set of conditions, but not under another set. An example is a gene with a temperature sensitive mutation.

35 Suppressible Translational Stop Codon

This describes a codon which allows the

translation of nucleotide sequences downstream of the codon under one set of conditions, but under another set of conditions translation ends at the codon. Example of suppressible translational stop codons are the amber, ochre and opal codons.

#### Mutator Strain

This is a host cell which has a genetic defect which causes DNA replicated within it to be mutated with respect to its parent DNA. Example mutator strains are NR9046mutD5 and NR9046 mut T1 (see Example 38).

#### Helper Phage

This is a phage which is used to infect cells containing a defective phage genome and which functions to complement the defect. The defective phage genome can be a phagemid or a phage with some function encoding gene sequences removed. Examples of helper phages are M13K07, M13K07 gene III no. 3; and phage displaying or encoding a binding molecule fused to a capsid protein.

#### Vector

This is a DNA molecule, capable of replication in a host organism, into which a gene is inserted to construct a recombinant DNA molecule.

#### Phage Vector

This is a vector derived by modification of a phage genome, containing an origin of replication for a bacteriophage, but not one for a plasmid.

#### Phagemid Vector

This is a vector derived by modification of a plasmid genome, containing an origin of replication for a bacteriophage as well as the plasmid origin of replication.

#### Secreted

This describes a rgdp or molecule that associates with the member of a sbp displayed on the rgdp, in which the sbp member and/or the molecule, have been folded and the package assembled externally to the cellular cytosol.

### Repertoire of Rearranged Immunoglobulin Genes

A collection of naturally occurring nucleotides eg DNA sequences which encoded expressed immunoglobulin genes in an animal. The sequences are generated by the  
5 in vivo rearrangement of eg V, D and J segments for H chains and eg the V and J segments for L chains. Alternatively the sequences may be generated from a cell line immunised in vitro and in which the rearrangement in response to immunisation occurs intracellularly. The  
10 word "repertoire" is used to indicate genetic diversity.  
Library

A collection of nucleotide eg DNA, sequences within clones; or a genetically diverse collection of polypeptides, or specific binding pair members, or  
15 polypeptides or sbp members displayed on rgdps capable of selection or screening to provide an individual polypeptide or sbp members or a mixed population of polypeptides or sbp members.

### Repertoire of Artificially Rearranged Immunoglobulin 20 Genes

A collection of nucleotide eg DNA, sequences derived wholly or partly from a source other than the rearranged immunoglobulin sequences from an animal. This may include for example, DNA sequences encoding VH  
25 domains by combining unrearranged V segments with D and J segments and DNA sequences encoding VL domains by combining V and J segments.

Part or all of the DNA sequences may be derived by oligonucleotide synthesis.

### 30 Secretory Leader Peptide

This is a sequence of amino acids joined to the N-terminal end of a polypeptide and which directs movement of the polypeptide out of the cytosol.

### Eluant

35 This is a solution used to breakdown the linkage between two molecules. The linkage can be a non-covalent or covalent bond(s). The two molecules can be

members of a sbp.

Derivative

This is a substance which derived from a polypeptide which is encoded by the DNA within a selected rgdp. The derivative polypeptide may differ from the encoded polypeptide by the addition, deletion, substitution or insertion of amino acids, or by the linkage of other molecules to the encoded polypeptide. These changes may be made at the nucleotide or protein level. For example the encoded polypeptide may be a Fab fragment which is then linked to an Fc tail from another source. Alternatively markers such as enzymes, flouresceins etc may be linked to eg Fab, scFv fragments.

According to one aspect of the present invention there is provided a method for producing multimeric specific binding pair (sbp) members, which method comprises

causing or allowing recombination between (a) first vectors comprising nucleic acid encoding a population of a fusion of a first polypeptide chain of a specific binding pair member and a component of a replicable genetic display package (rgdp) and (b) second vectors comprising nucleic acid encoding a population of a second polypeptide chain of a specific binding pair member, at least one of said populations being genetically diverse, the recombination resulting in recombinant vectors each of which comprises nucleic acid encoding a said polypeptide fusion and a said second polypeptide chain and capable of being packaged into rgdps using said rgdp component.

One or other or both of the populations of first and second polypeptide chains may be genetically diverse. Where both are genetically diverse, the recombinant vectors will represent an enormously diverse repertoire of sbp members. Either or both of the populations may be genetically diverse but restricted

compared with the full repertoire available, perhaps by virtue of a preceding selection or screening step. A library of nucleic acid encoding a restricted population of polypeptide chains may be the product of selection or  
5 screening using rgdp display.

According to another aspect of the invention there is provided a method of producing multimeric specific binding pair (sbp) members, which method comprises:

10 (i) expressing from a vector in recombinant host organism cells a population of a first polypeptide chain of a specific binding pair member fused to a component of a replicable genetic display package (rgdp) which thereby displays said polypeptide chains at the surface  
15 of rgdps, and combining said population with a population of a second polypeptide chain of said specific binding pair member by causing or allowing first and second polypeptide chains to come together to form a library of said multimeric specific binding pair  
20 members displayed by rgdps, said population of second polypeptide chains not being expressed from the same vector as said population of first polypeptide chains, at least one of said populations being genetically  
25 diverse and expressed from nucleic acid that is capable of being packaged using said rgdp component, whereby the genetic material of each said rgdp encodes a polypeptide chain of a said genetically diverse population;

(ii) selecting or screening rgdps formed by said  
30 expressing to provide an individual sbp member or a mixed population of said sbp members associated in their respective rgdps with nucleic acid encoding a polypeptide chain thereof;

(iii) obtaining nucleic acid from a selected or screened rgdp, the nucleic acid obtained being one of  
35 (a) nucleic acid encoding a first polypeptide chain, (b) nucleic acid encoding a second polypeptide chain, and (c) a mixture of (a) and (b);

(iv) producing a recombinant vector by causing or allowing recombination between (a) a vector comprising nucleic acid obtained in step (iii) encoding a first polypeptide chain and a vector comprising nucleic acid encoding a second polypeptide chain, or (b) a vector comprising nucleic acid encoding a first polypeptide chain and a vector comprising nucleic acid obtained in step (iii) encoding a second polypeptide chain.

The recombination may take place intracellularly or in vitro, although it is preferable that it takes place in recombinant host cells. This is discussed elsewhere, but briefly this may involve introducing a library of vectors including nucleic acid encoding first (or second) polypeptide chain components of sbp member into host cells harbouring a library of vectors comprising nucleic acid encoding second (or first) polypeptide chain components of sbp members.

Following the recombination the polypeptide fusions (first polypeptide chains fused to a rgdp component) and the second polypeptide chains may be expressed, producing rgdps which display at their surface said first and second polypeptide chains and which each comprise nucleic acid encoding a said first polypeptide chain and a said second polypeptide chain, by virtue of the packaging of the recombinant vectors into rgdps. This expression may therefore produce an extremely diverse library of sbp members displayed on rgdp. In one embodiment, the rgdps displaying sbp member are pAbs (ie phage displaying antibodies or antibody fragments or derivatives), and those which bind antigen of interest may be selected using their binding capability. Since each pAb contains within it nucleic acid encoding both polypeptide chains of the antibody displayed on its surface, pAbs selected by binding to an antigen of interest will provide nucleic acid encoding an antibody which binds that antigen. The nucleic acid may be isolated from the selected pAbs and used in

subsequent obtention of desired antibodies, after any amplification and cloning required in a given case.

The recombination may be promoted by inclusion in the vectors of sequences at which site-specific recombination will occur. This enables accurate design of the resultant recombinant vectors. For instance, a sequence at which site-specific recombination will occur may be position in the nucleic acid which encodes a polypeptide linker which joins the two domains of a single chain sbp member. The single chain sbp member may consist of an immunoglobulin VH domain linked to an immunoglobulin VL domain. VH and VL domains may associate to form an antigen binding site. The resultant recombinant vector may then comprise nucleic acid encoding a single chain Fv derivative of an immunoglobulin resulting from recombination between first and second vectors. (Note: a single chain sbp member, such as a scFv fragment or derivative of an antibody, may be considered to be multimeric (dimeric) because it consists of two polypeptide chain domains, such as VL and VH of an antibody.)

The sequences at which site-specific recombination will occur may be loxP sequences obtainable from coliphage P1, with site-specific recombination catalysed by Cre-recombinase, also obtainable from coliphage P1. The site-specific recombination sequences used may be derived from a loxP sequence obtainable from coliphage P1.

The Cre-recombinase used may be expressible under the control of a regulatable promoter.

In order to increase the efficiency of the method, increasing the proportion of productive recombination leading to the resultant recombinant vectors desired, each vector may include two site-specific recombination sequences each of which is different from the other. The sequences should then be such that recombination will take place between like



sequences on different vectors but not between the different sequences on the same vector.

Each of the first vectors and each of the second vectors may include a first site-specific recombination sequence and a second site-specific recombination sequence different from the first, site-specific recombination taking place between first site-specific recombination sequences on different vectors and between second site-specific recombination sequences on different vectors but not between a first site-specific recombination sequence and a second site-specific recombination sequence on the same vector.

The first site-specific recombination sequence may be loxP obtainable from coliphage P1 and the second site-specific recombination sequence a mutant loxP sequence, or vice versa. Potentially, both the first and second site-specific recombination sequences may be mutants, as long as the first sequence will not recombine with the second sequence but first sequences will recombine with each other and second sequences will recombine with each other.

A suitable mutant loxP sequence is loxP 511.

The first vectors may be phages or phagemids and the second vectors plasmids, or the first vectors may be plasmids and the second vectors phages or phagemids.

In one embodiment, the recombination is intracellular and takes place in a bacterial host which replicates the recombinant vector preferentially over the first vectors and the second vectors. This may be used to enrich selection of successful recombination events. The intracellular recombination may take place in a bacterial host which replicates plasmids preferentially over phages or phagemids, or which replicates phages or phagemids preferentially over plasmids. For instance, the bacterial host may be a PolA strain of E.coli or of another gram-negative bacterium. PolA cells are unable to support replication

of plasmids, but can support replication of filamentous phage and phagemids (plasmids containing filamentous phage intergenic regions). So, for instance, if the first vectors are plasmids containing a first marker gene, and the second vectors are phage or phagemids containing a second marker gene, selection for both markers will yield recombinant vectors which are the product of a successful recombination event, since recombination transferring the first marker from plasmid must take place in order for that marker to be replicated and expressed.

Nucleic acid from one or more rgdp's may be taken and used in a further method to obtain an individual sbp member or a mixed population of sbp members, or polypeptide chain components thereof, or encoding nucleic acid therefor.

The present invention also provides a kit for use in carrying out methods provided, having:

(i) a first vector having a restriction site for insertion of nucleic acid encoding or a polypeptide component of an sbp member, said restriction site being in the 5' end region of the mature coding sequence of a phage capsid protein, with a secretory leader sequence upstream of said site which directs a fusion of the capsid protein and sbp polypeptide to the periplasmic space of a bacterial host; and

(ii) a second vector having a restriction site for insertion of nucleic acid encoding a second said polypeptide chain,

at least one of the vectors having an origin of replication for single-stranded bacteriophage, the vectors having sequences at which site-specific recombination will occur.

The kit may contain ancillary components needed for working the method.

Also provided by the present invention are recombinant host cells harbouring a library of first

vectors each comprising nucleic acid encoding a first polypeptide chain of a sbp member fused to a component of a secretable replicable genetic display package (rgdp) and second vectors each comprising nucleic acid  
5 encoding a second polypeptide chain of a sbp member, the first vectors or the second vectors or both being capable of being packaged into rgdps using the rgdp component, and the vectors having sequences at which site-specific recombination will occur.

10 According to another aspect of the present invention there is provided a population of rgdps each displaying at its surface a sbp member and each containing nucleic acid which encodes a first and a second polypeptide chain of the sbp member displayed at  
15 its surface and which includes a site-specific recombination sequence.

According to another aspect of the invention there is provided a population of rgdps each displaying at its surface a sbp member and each containing nucleic  
20 acid which comprises a combination of (i) nucleic acid encoding a first polypeptide chain of a sbp member and (ii) nucleic acid encoding a second polypeptide chain of a sbp member, the population containing  $10^{10}$  or more combinations of (i) and (ii). Such a population exceeds  
25 in size the maximum which is achievable using available techniques. The present invention enables production of enormously diverse libraries or populations of rgdps displaying sbp members. The nucleic acid encoding a first polypeptide chain of a sbp member may have, for  
30 instance,  $10^7$  different sequences throughout the population. Where the nucleic acid encoding a second polypeptide chain of a sbp member also has such a genetic diversity throughout the population, the number of different combinations of nucleic acid encoding first  
35 and second polypeptide chains is immense.

Embodiments of the present invention will now be described in more detail by way of example only and not by way of limitation, with reference to the figures.

## 5 BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 shows plots of the probability of isolating an antibody with a given  $p[K]$  value against the size of a library.

Fig. 2 outlines a strategy to clone heavy chain as  
10 g3 fusion on phage, light chain being expressed as soluble fragments from a phagemid.

Fig. 3 (i) and (ii) illustrates the use of sites specific recombination for construction of  
polycombinatorial libraries.

15 Fig 4A shows replicons generated by Cre mediated recombination between the acceptor phage vector fdDOG-2lox (A) and the donor plasmid vector pUC19-2lox (B). A is based on fd-tet-DOG1, with Vk from the mouse anti-phOx antibody NQ10.12.5 linked to a human Ck  
20 constant domain, and VH from the mouse anti-TNFA antibody linked to a human Cml constant domain. B is based on pUC19, with VH of NQ10.12.5 linked to the human Cg1 constant domain. Within E. coli an equilibrium  
25 between the six vectors develops due to the reversible nature of recombination in the lox-Cre system. Ribosome-binding sites (small open circles), c-myc peptide tag (myc), phage fd gene III leader peptide sequence (Lg3), pelB leader peptide sequence (LpelB), fd  
30 phage gene III (gIII) and locations of oligonucleotides used for hybridisation and screening are indicated.

Fig 4B shows the sequence across the wild-type loxP and mutant loxP 511 sites present in fdDOG-2lox (A) and pUC19-2lox (B). The inverted repeats in the loxP sites are boxed and the position of the point mutation in the

mutant loxP 511 site is indicated (#), as are the ribosome-binding sites (r.b.s.). Note that the wild-type loxP sites are in frame to ensure that the heavy chains immediately upstream can be fused to gene III for

5 display on phage.

Fig. 5 shows schematically selection techniques which utilise the unique properties of pAbs; 5(i) shows a binding/elution system; and 5(ii) shows a competition system (p=pAb; ag=antigen to which binding by pAb is  
10 required; c=competitor population e.g. antibody, pAb, ligands; s=substrate (e.g. plastic beads etc); d=detection system.

Disclosed here are methods useful for preparing  
15 extremely diverse libraries of specific binding pair members, such as antibody heavy and light chains. Heavy and light chains cloned on separate replicons may be introduced into host cells. The heavy and light chain genes are recombined onto the same replicon such that  
20 the final number of combinations created is the number of heavy chains multiplied by the number of light chains. Recombination can occur in vivo or in vitro. Preferably, the recipient replicon is capable of being incorporated into an rgdp such that functional  
25 combinations of heavy and light chain genes can be selected. Such a format is particularly advantageous for construction of extremely diverse libraries of antibody heavy and light chains, for example, from unimmunised donors, immunised donors or a repertoire of an  
30 artificially rearranged immunoglobulin gene or genes, and is also convenient for chain-shuffling, mutagenesis, humanising and CDR 'imprinting'.

These methods can also be applied to other proteins in which two or more subunits assemble to create a

functional oligomer.

The genes for both subunits present on two separate replicons can be brought together onto the same rgdp such that favourable combinations of subunit genes may  
5 be isolated directly without recourse to extensive recloning. This may be achieved by recombination between the replicons once they have been introduced into the same cell. In a preferred configuration, recombination events are effected such that the genes for one of the  
10 chains is recombined onto a recipient replicon which contains the gene for a partner chain. Preferably, the recipient replicon is capable of being packaged into an rgdp. Most preferably, the genes encoding one or more of the subunits is fused to a capsid gene such as gIII in  
15 order that the functional multimer can be displayed on the surface of the rgdp.

A variety of recombination systems are known, and many of these could be harnessed in such a way as to effect recombination between replicons. Example  
20 recombination systems include general recombination, transposition and site-specific recombination.

General recombination is a process whereby genetic exchange occurs between DNA segments that share some homology, and is also known as 'homologous  
25 recombination'. It is the principal mechanism by which genetic material is transferred between chromosomes, and in E.coli the process is catalysed by the rec BCD enzyme (In "Escherichia coli and Salmonella typhimurium. Cellular and Molecular Biology." (1987). pp1034-1043.  
30 Neidhart, F.C. Editor in Chief. American Society for Microbiology). A general recombination mechanism could be used to transfer genes from one replicon to the other if, for example, the rgdp genome has a gene for one of the chains and a 'dummy' partner chain gene such that

recombination would have to occur to replace the dummy gene on the rgdp replicon with the functional gene on the second replicon in order to produce a functional pairing.

- 5 Transposition could also be used to effect transfer of genetic information from one replicon to another (In "Escherichia coli and Salmonella typhimurium. Cellular and Molecular Biology." (1987). pp1061-1070. Neidhart, F.C. Editor in Chief. American Society for
- 10 Microbiology). Transposons such as Tn 3 and Tn 10 are DNA segments that have also been called 'jumping genes' and 'selfish DNA' and are found on plasmids and in the E.coli chromosome. Transposon structure is variable, but usually comprises recombinase genes flanked by repeated
- 15 DNA sequences; the recombinase(s) together with host factors catalyse insertion of the transposon into sites on the chromosome, by a mechanism which usually results in a duplication of site at which the transposon has inserted. Insertion by some transposons can be highly
- 20 site-specific whereas others insert essentially at random. For the purpose of transferring genes from one replicon to another, the donor gene could be incorporated within a highly site specific transposon such as Tn 7. The recipient plasmid would be engineered
- 25 to contain the target DNA sequence.

- One of the most fully understood site-specific recombination systems is that used in integration and excision of bacteriophage lambda (In "Escherichia coli and Salmonella typhimurium. Cellular and Molecular
- 30 Biology." (1987). pp1054-1060. Neidhart, F.C. Editor in Chief. American Society for Microbiology). This bacteriophage can follow two developmental pathways once inside the cell: lysis or lysogeny. The lysogenic pathway involves integration of the lambda genome into

the chromosome of the infected bacterium; integration is the result of a site-specific recombination between a ca. 240bp sequence in the bacteriophage called att P and a 25bp site in the bacterial chromosome called att B.

5 The integration event is catalysed by a host encoded factor called IHF and a phage encoded enzyme called Int recombinase, which recognises a 15bp region common to the two att sites. The integrated DNA is flanked by sequences derived from att B and att P, and these are

10 called att L and att R. The integration event is reversible and is catalysed by Int, IHF and a second bacteriophage encoded enzyme, Xis. It is envisaged that this system could be used for sequence transfer between replicons within E.coli. For example, the donor gene

15 could be flanked by att L and att R sites such that when Int and Xis proteins are provided in the host cell, recombination between att L and att R. sites would create a circular DNA segment containing the donor gene and a recreated att B site. This circular segment could

20 then recombine with an att P site engineered into the recipient plasmid.

An alternative site specific recombination system is the lox P/Cre recombinase system of coliphage P1 (Hoess, R.H. and Abremski, K. (1990) The Cre-lox

25 recombination system. In 'Nucleic acids and Molecular Biology.' Eckstein, F. and Lilley, D.M.J. eds. Vol 4, pp99-109, Springer-Verlag, Berlin, Heidelberg).

Cre-recombinase catalyses a highly specific recombination event at sequences called lox. lox P, the

30 recombination site in phage P1 consists of two 13bp inverted repeats separated by an 8bp non-symmetrical core (fig 3). For the work descended in this application, the lox P/Cre system was chosen of the alternatives available because the recombination is



highly sequence-specific, very efficient and occurs at a short target site that is readily incorporated into cloning vectors.

In the example outlined configuration in fig 3  
5 soluble light chain is cloned onto a phagemid containing a single lox P site. The heavy chains are cloned onto a plasmid as g3 fusions. Alongside the g3 fusion is the gene for a selectable marker, and the  
heavychain/g3/marker sequence flanked by two lox P  
10 sites. This plasmid also contains the Cre recombinase on a regulatable promoter and has an origin of double-stranded replication that is compatible with that on the phagemid in addition to that on the helper phage e.g. p15A, RSF 1010 and col E1 origins will co-exist in  
15 the same cell. The phagemids are then infected into cells containing the donor plasmid and the Cre recombinase promoter induced, so that recombination between the lox P sites occurs inside infected cells. Some of these recombination events will lead to the  
20 heavychain/g3/marker sequences transferring as a block onto the phagemid at its single lox P site. Phagemids are then rescued with a helper phage such as M13K07 (see WO92/01047) and the resulting phagemid particles either directly selected on antigen or infected into fresh host  
25 cells and grown with selection for the presence of both markers; one from the phagemid itself and the other from the heavychain/g3/marker block.

The use of site-specific recombination to bring genes onto the same replicon may be extended to creation  
30 of a continuous coding sequence on the same replicon, for example to construct single-chain Fv molecules. There is a single open reading frame in the loxP sequence that could be incorporated into an scFv linker which would then be a substrate for Cre-catalysed

site-specific recombination. Placement of such modified scFv linker sequences at one or both ends of the genes to be fused can then result in creation of continuous open reading frames in vivo or in vitro when Cre  
5 recombinase is provided.

As with other site-specific recombination systems, Cre-catalysed recombination is reversible such that productive recombinants form only a fraction of the recombinants. Selection of productive rearrangements may  
10 be facilitated by use of a polA strain of bacteria, preferably E.coli or other gram negative bacterium. These cells are deficient in DNA polymerase I and are unable to support replication of plasmids (Johnston, S. and Ray, D.S. 1984, supra.). However, they are able to  
15 support replication of filamentous phage and plasmids containing filamentous phage intergenic regions. If Cre-catalysed recombination is performed in polA bacteria, by selecting for the presence of both selectable markers in the same pol A cell successful recombination events  
20 are enriched, since recombination must take place for the second marker gene to be replicated and expressed. The resulting cells then contain the complete repertoire and can be propagated as cells and infected with helper phage to produce phagemids containing the genes for both  
25 chains and expressing them on their surface.

Another way of enriching for productive recombination events is to employ mutant loxP sites. Several mutants of the loxP sequence are known, and these are compromised with respect to their ability to  
30 recombine with each other and the wild-type loxP sequence (Hoess, R.H., Wierzbicki, A. and Abremski, K. (1986) Nucl. Acids Res. 14, 2287-2300). For example, loxP 511 has a G->A point mutation in the central 8bp segment, with the result that it will only recombine

- with other loxP 511 sites, but not the wild-type loxP sequence (Hoess, R.H., Wierzbicki, A. and Abremski, K. (1986) et supra.). Placement of wild-type and mutant loxP sequence combinations can direct which
- 5 recombination events are possible: their use is described in example 1. Other mutant loxP sites are known but their abilities to recombine with each other and the wild-type loxP sequence have not been extensively characterised, presumably loxP 511 is not
- 10 unique. Provision of different mutant loxP sites in the vectors would permit even greater control over the occurrence of recombination events perhaps leading to more complex, controllable and efficient recombination strategies being possible.
- 15 The presence of target DNA sequences for site-specific recombination in the vectors has utility for subsequent manipulation of the genes. Naturally occurring or artificially introduced loxP sequences in the genomes of prokaryotic and eukaryotic organisms can
- 20 be used as target sites for insertion of genes. Moreover, since Cre-catalysed recombination occurs readily in vitro, rapid and efficient transfer of genes in vitro, for example between different vectors, is also contemplated (Boyd, A.C. (1993) Nuc. Acids Res. 21,
- 25 817-821)
- It will be apparent that the concept of using two or more replicons to generate diversity is not confined to display of multimers on the surface of filamentous bacteriophages. For example, bacteria could be used as
- 30 the replicable genetic display package. For example, Fuchs et al. have shown that functional antibody can be displayed on the surface of E.coli by fusion to peptidoglycan-associated lipoprotein (Fuchs, P., Breitling, F., Dubel, S., Seehaus, T and Little, M.

- (1991) Targetting of recombinant antibodies to the surface of *Escherichia coli*: fusion to a peptidoglycan associated lipoprotein. *BioTechnology* 9, 1369-1373.). Klauser et al. describe transport of a heterologous protein to the surface of *E.coli* by fusion to *Neisseria* IgA protease (Klauser, T., Pohler, J. and Meyer, T.F. (1990) Extracellular transport of cholera toxin B subunit using *Neisseria* IgA protease B domain: conformation-dependent outer membrane translocation. *EMBO* 9, 1991-1999). Other surface proteins such as pili, ompA or the surface-exposed lipoprotein Tra T could also be used, and gram positive organisms such as *Lactobacilli* and *Streptococci* employed. Cloning and expression in Eukaryotic organisms is also contemplated.
- Alternative cloning strategies are possible when cells are used in place of phage. For example, replicons can be introduced into the cells by conjugation, in addition to transformation and infection. Moreover, one or more genes can be recombined or transposed into the chromosome reducing the limitation of having to use compatible replicons.

The polycombinatorial concept is also particularly advantageous for mutagenesis experiments by allowing far greater numbers of mutant progeny to be produced. For example, if the genes encoding a multimeric peptide or polypeptide are mutated at a total of 10 amino acid positions, to incorporate any amino acid at these positions, then the total number of combinations is  $20^{10} \Rightarrow 1.024 \cdot 10^{13}$ . This figure is way beyond the reach of standard cloning formats, but can be achieved using the approaches described here.

The methods described here are applicable to multimeric proteins other than antibodies, such as T cell receptors, CD3 and insulin receptor. Libraries of

proteins having more than two different and diverse subunits can be created by, for example, more than one cycle of infection. Cells containing one of the subunits are infected with phage containing the second subunit  
5 and the resulting population infected a second time with a compatible phage carrying the third subunit.

In some cases, it is advantageous to express all components of the multimer as g3 fusions. This will have the benefit stabilising weak interactions between  
10 separate chains, e.g. VHg3 and VLg3 to create phage or phagemid particles with both VH and VL fused to g3 on the same particle, or stabilising polypeptides which interact weakly, or polypeptides which only associate in the presence of ligand.

15 The numbers of combinations possible with the polycombinatorial approach is limited only by the number of clones present in each of the repertoires, and, in the specific instance of using phage supplying one chain to infect cells containing the other, by the numbers of  
20 phage and cells that can be produced. The use of more sophisticated methods, for example fermentation technology, will allow even greater numbers of combinations to be accessed.

25 The nucleic acid encoding first and second polypeptide components of antibodies may be derived from the repertoire of an immunised or unimmunised animal or human, or from an artificially rearranged immunoglobulin gene or genes. Artificial rearrangement of  
30 immunoglobulin genes may involve joining of germ-line V segments in vitro to J segments and, in the case of VH domains, D segments. Any of the V, D and J segments may be synthetic. The joining may use a PCR-based process which may use primers which have a region of random

sequence to introduce sequence diversity into the product, artificially rearranged immunoglobulin genes.

Filamentous F-specific bacteriophages are suitable examples of the type of phage which provide a vehicle for the display of binding molecules e.g. antibodies and antibody fragments and derivatives thereof, on their surface and facilitate subsequent selection and manipulation.

10 The F-specific phages (e.g. fl, fd and M13) have evolved a method of propagation which does not kill the host cell and they are used commonly as vehicles for recombinant DNA (Kornberg, A., DNA Replication, W.H. Freeman and Co., San Francisco, 1980). Gene III of  
15 phage fd is attractive for the insertion of biologically active foreign sequences. There are however, other candidate sites including for example gene VIII and gene VI.

The protein encoded by gene III has several domains  
20 (Pratt, D., et al., 1969 Virology 39:42-53., Grant, R.A., et al., 1981, J. Biol. Chem. 256: 539-546 and Armstrong, J., et al., FEBS Lett. 135: 167-172 1981).

The gene coding sequences for biologically active antibody fragments have been inserted into the gene III  
25 region of fd to express a large fusion protein. An initial vector used was fd-tet (Zacher, A.N., et al., 1980, Gene 9, 127-140) a tetracycline resistant version of fd bacteriophage that can be propagated as a plasmid that confers tetracycline resistance to the infected  
30 E.coli host. The applicants chose to insert after the signal sequence of the fd gene III protein for several reasons. In particular, the applicants chose to insert after amino acid 1 of the mature protein to retain the context for the signal peptidase cleavage. To retain

the structure and function of gene III itself, the majority of the original amino acids are synthesized after the inserted immunoglobulin sequences. The inserted immunoglobulin sequences were designed to  
5 include residues from the switch region that links VH-VL to CH1-CL (Lesk, A., and Chothia, C., Nature 335, 188-190, 1988).

By manipulating gene III of bacteriophage fd, one can construct a bacteriophage that displays on its  
10 surface large biologically functional antibody, enzyme, and receptor molecules whilst remaining intact and infectious. Furthermore, the phages bearing antibodies of desired specificity, can be selected from a background of phages not showing this specificity.

15 The sequences coding for a population of antibody molecules and for insertion into the vector to give expression of antibody binding functions on the phage surface can be derived from a variety of sources. For example, immunised or non-immunised rodents or humans,  
20 and from organs such as spleen and peripheral blood lymphocytes. The coding sequences are derived from these sources by techniques familiar to those skilled in the art (Orlandi, R., et al., 1989 supra; Larrick, J.W., et al., 1989 supra; Chiang, Y.L., et al., 1989 Bio  
25 Techniques 7, p. 360-366; Ward, E.S, et al., 1989 supra; Sastry, L., et al., 1989 supra.)

In standard recombinant techniques for the production of antibodies, an expression vector containing sequences coding for the antibody polypeptide  
30 chains is used to transform e.g. E.coli. The antibody polypeptides are expressed and detected by use of standard screening systems. When the screen detects an antibody polypeptide of the desired specificity, one has to return to the particular transformed E.coli.

expressing the desired antibody polypeptide.  
Furthermore, the vector containing the coding sequence  
for the desired antibody polypeptide then has to be  
isolated for use from E.coli in further processing  
5 steps.

In the present invention however, the desired  
antibody polypeptide when expressed, is already packaged  
with its gene coding sequence. This means that when the  
an antibody polypeptide of desired specificity is  
10 selected, there is no need to return to the original  
culture for isolation of that sequence. Furthermore, in  
previous methods in standard recombinant techniques,  
each clone expressing antibody needs to be screened  
individually. The present application provides for the  
15 selection of clones expressing antibodies with desired  
properties.

Because a rgdp (eg a pAb) displays a member of a  
specific binding pair (eg. an antibody of monoclonal  
antigen-binding specificity) at the surface of a  
20 relatively simple replicable structure also containing  
the genetic information encoding the member, rgdps eg  
pAbs, that bind to the complementary member of the  
specific binding pair (eg antigen) can be recovered very  
efficiently by either eluting off the complementary  
25 member using for example diethylamine, high salt etc and  
infecting suitable bacteria, or by denaturing the  
structure, and specifically amplifying the sequences  
encoding the member using PCR. That is, there is no  
necessity to refer back to the original bacterial clone  
30 that gave rise to the pAb.

#### SELECTION FORMATS AND AFFINITY MATURATION

Individual rgdps eg pAbs expressing the desired  
specificity eg for an antigen, can be isolated from the



complex library using the conventional screening techniques (e.g. as described in Harlow, E., and Lane, D., 1988, supra Gherardi, E et al. 1990. J. Immunol. meth. 126 p61-68).

- 5        Other selection techniques, described and illustrated in WO 92/01047, are practicable only because of the unique properties of rgdps. The general outline of some screening procedures is illustrated in figure 5 using pAbs as an example type of rgdp.
- 10       The population/library of pAbs to be screened could be generated from immunised or other animals; or be created in vitro by mutagenising pre-existing phage antibodies (using techniques well-known in the art such as oligonucleotide directed mutagenesis (Sambrook, J.,
- 15       et al., 1989 Molecular Cloning a Laboratory Manual, Cold Spring Harbor Laboratory Press). This population can be screened in one or more of the formats described below with reference to figure 5, to derive those individual pAbs whose antigen binding properties are different from
- 20       sample c.

#### Binding Elution

- Figure 5(1) shows antigen (ag) bound to a solid surface (s) the solid surface (s) may be provided by a petri dish, chromatography beads, magnetic beads and the
- 25       like. The population/library of pAbs is then passed over the ag, and those individuals p that bind are retained after washing, and optionally detected with detection system d. A detection system based upon anti-fd antisera is illustrated in more detail in example 4
- 30       of WO 92/01047. If samples of bound population p are removed under increasingly stringent conditions, the binding affinity represented in each sample will increase. Conditions of increased stringency can be obtained, for example, by increasing the time of soaking

or changing the pH of the soak solution, etc.

#### Competition

Referring to figure 5(ii) antigen ag can be bound to a solid support s and bound to saturation by the original binding molecule c. If a population of mutant pAb (or a set of unrelated pAbs) is offered to the complex, only those that have higher affinity for antigen ag than c will bind. In most examples, only a minority of population c will be displaced by individuals from population p. If c is a traditional antibody molecule, all bound material can be recovered and bound p recovered by infecting suitable bacteria and/or by use of standard techniques such as PCR.

An advantageous application is where ag is used as a receptor and c the corresponding ligand. The recovered bound population p is then related structurally to the receptor binding site/and or ligand. This type of specificity is known to be very useful in the pharmaceutical industry.

Another advantageous application is where ag is an antibody and c its antigen. The recovered bound population p is then an anti-idiotypic antibody which have numerous uses in research and the diagnostic and pharmaceutical industries.

At present it is difficult to select directly for anti-idiotypic antibodies. pAbs would give the ability to do this directly by binding pAb libraries (eg a naive library) to B cells (which express antibodies on their surface) and isolating those phage that bound well.

In some instances it may prove advantageous to pre-select population p. For example, in the anti-idiotypic example above, p can be absorbed against a related antibody that does not bind the antigen.

However, if c is a pAb, then either or both c and p

can advantageously be marked in some way to both distinguish and select for bound p over bound c. This marking can be physical, for example, by pre-labelling p with biotin; or more advantageously, genetic. For  
5 example, c can be marked with an EcoB restriction site, whilst p can be marked with an EcoK restriction site (see Carter, P. et al., 1985, Nucl. Acids Res. 13, 4431-4443). When bound p+c are eluted from the antigen and used to infect suitable bacteria, there is restriction  
10 (and thus no growth) of population c (i.e. EcoB restricting bacteria in this example). Any phage that grew, would be greatly enriched for those individuals from p with higher binding affinities. Alternatively, the genetic marking can be achieved by marking p with  
15 new sequences, which can be used to specifically amplify p from the mixture using PCR.

Since the bound pAbs can be amplified using for example PCR or bacterial infection, it is also possible to rescue the desired specificity even when insufficient  
20 individuals are bound to allow detection via conventional techniques.

The preferred method for selection of a phage displaying a protein molecule with a desired specificity or affinity will often be elution from an affinity  
25 matrix with a ligand (eg example 21 of WO 92/01047). Elution with increasing concentrations of ligand should elute phage displaying binding molecules of increasing affinity. However, when eg a pAb binds to its antigen with high affinity or avidity (or another protein to its  
30 binding partner) it may not be possible to elute the pAb from an affinity matrix with molecule related to the antigen. Alternatively, there may be no suitable specific eluting molecule that can be prepared in sufficiently high concentration. In these cases it is

necessary to use an elution method which is not specific to eg the antigen-antibody complex. Some of the non-specific elution methods generally used reduce phage viability for instance, phage viability is reduced with  
5 time at pH12 (Rossomando, E.F. and Zinder N.D. J. Mol.Biol. 36 387-399 1968). There may be interactions between eg antibodies and affinity matrices which cannot be disrupted without completely removing phage infectivity. In these cases a method is required to  
10 elute phage which does not rely on disruption of eg the antibody - antigen interaction. A method was therefore devised which allows elution of bound pAbs under mild conditions (reduction of a dithiol group with dithiothreitol) which do not disrupt phage structure  
15 (example 47 of WO 92/01047).

This elution procedure is just one example of an elution procedure under mild conditions. A particularly advantageous method would be to introduce a nucleotide sequence encoding amino acids constituting a recognition  
20 site for cleavage by a highly specific protease between the foreign gene inserted, in this instance a gene for an antibody fragment, and the sequence of the remainder of gene III. Examples of such highly specific proteases are Factor X and thrombin. After binding of the phage  
25 to an affinity matrix and elution to remove non-specific binding phage and weak binding phage, the strongly bound phage would be removed by washing the column with protease under conditions suitable for digestion at the cleavage site. This would cleave the antibody fragment  
30 from the phage particle eluting the phage. These phage would be expected to be infective, since the only protease site should be the one specifically introduced. Strongly binding phage could then be recovered by infecting eg. E.coli TG1 cells.

An alternative procedure to the above is to take the affinity matrix which has retained the strongly bound pAb and extract the DNA, for example by boiling in SDS solution. Extracted DNA can then be used to  
5 directly transform E.coli host cells or alternatively the antibody encoding sequences can be amplified, for example using PCR with suitable primers such as those disclosed herein, and then inserted into a vector for expression as a soluble antibody for further study or a  
10 pAb for further rounds of selection.

Another preferred method for selection according to affinity would be by binding to an affinity matrix containing low amounts of ligand.

If one wishes to select from a population of phages  
15 displaying a protein molecule with a high affinity for its ligand, a preferred strategy is to bind a population of phage to an affinity matrix which contains a low amount of ligand. There is competition between phage, displaying high affinity and low affinity proteins, for  
20 binding to the ligand on the matrix. Phage displaying high affinity protein is preferentially bound and low affinity protein is washed away. The high affinity protein is then recovered by elution with the ligand or by other procedures which elute the phage from the  
25 affinity matrix (example 35 of WO 92/01047 demonstrates this procedure).

In summary then, for recovery of the packaged DNA from the affinity step, the package can be simply eluted, it can be eluted in the presence of a homologous  
30 sbp member which competes with said package for binding to a complementary sbp member; it could be removed by boiling, it could be removed by proteolytic cleavage of the protein; and other methods will be apparent to those skilled in the art eg. destroying the link between the

substrate and complementary sbp member to release said packaged DNA and sbp member. At any rate, the objective is to obtain the DNA from the package so that it can be used directly or indirectly, to express the sbp member  
5 encoded thereby.

The efficiency of this selection procedure for pAbs and the ability to create very large libraries means that the immunisation techniques developed to increase the proportion of screened cells producing antibodies of  
10 interest will not be an absolute requirement. The technique allows the rapid isolation of binding specificities eg antigen-binding specificities, including those that would be difficult or even unobtainable by conventional techniques, for example,  
15 catalytic or anti-idiotypic antibodies. Removal of the animal altogether is now possible, once a complete library of the immune repertoire has been constructed.

The structure of the pAb molecule can be used in a number of other applications, some examples of which  
20 are:

#### Signal Amplification

Acting as a molecular entity in itself, rgdps eg pAbs combine the ability to bind a specific molecule eg antigen with amplification, if the major coat protein is  
25 used to attach another moiety. This moiety can be attached via immunological, chemical, or any other means and can be used, for example, to label the complex with detection reagents or cytotoxic molecules for use in vivo or in vitro.

#### 30 Physical Detection

The size of the rgdps eg pAbs can be used as a marker particularly with respect to physical methods of detection such as electron microscopy and/or some biosensors, e.g. surface plasmon resonance.

Diagnostic Assays

The rgdps eg pAbs also have advantageous uses in diagnostic assays, particularly where separation can be effected using their physical properties for example  
5 centrifugation, filtration etc.

Example 1: In vivo recombination of antibody genes between replicons using Cre/lox

10 This example illustrates using the Cre/loxP system to transfer antibody genes between two replicons in the same cell. Here, recombination must occur to produce a functional pairing of antibody genes.

Two constructs were made: an "acceptor" fd phage  
15 vector, fdDOG-2lox (A) and a "donor" plasmid vector, pUC19-2lox (B) (see Fig 4. and legend). A encodes the light chain of a first antibody (and the heavy chain from a second, different antibody): B encodes the heavy chain of the first antibody. In both vectors the VH  
20 genes are flanked by two loxP sites (see Fig 4.). To avoid deletion of the VH genes in the presence of Cre, one of the loxP sites is wild-type but the other contains a G to A point mutation within the 8 bp spacer region loxP 511 (Hoess, R.H., Wierzbicki, A. and  
25 Abremski, K. (1986) et supra.). The wild-type loxP site and the mutant loxP 511 site do not recombine with each other in the same vector, but will, as shown below, recombine with sites of matching sequence in different vectors. When Cre recombinase is provided in vivo by  
30 infecting the E. coli with phage PlCm cl.100 (Rosner, J.L. (1972) Virology, 48, 679-689), A and B can co-integrate by recombination between either mutant or wild-type loxP sites to create chimaeric plasmids C or D respectively. Further recombination can then occur

between the two wild-type or the two mutant loxP sites, to generate the original vectors (A and B) or two new vectors (E and F). The heavy chains of A and B are therefore exchanged, and E now encodes the Fab fragment  
5 of the first antibody for display as a fusion to the N-terminus of the phage gene 3 protein (g3p).

(a) Construction of fdDOG-2lox and pUC19-2lox vectors.

FdDOG-2lox and pUC19-2lox vectors were derived from  
10 fdDOG-1 and pUC19 respectively (WO 92/01047 and WO 92/20791; fdDOG-1 previously called fdCAT-2). The cloning sites of these vectors were engineered using a combination of site-directed mutagenesis and ligation of  
15 double-stranded synthetic oligonucleotides using standard molecular biology techniques (Sambrook, J., Fritsch, E.F. and Maniatis, T. (1990) "Molecular cloning-a laboratory manual". Cold Spring Harbor Laboratory, New York.).

These constructs were used to produce donor plasmid B  
20 and acceptor phage A depicted in figure 4. Plasmid B contains the VH gene of the anti-phOx (2-phenyloxazol-5-one) hybridoma NQ10.12.5 (Griffiths, G.M., Berek, C., Kaartinen, M. and Milstein, C. (1984) Nature , 312, 271-275.) linked to a human Cg1 segment,  
25 and cloned into pUC19-2lox as an Sfi 1-Not 1 fragment. Acceptor phage A contains the VL partner of the anti-phOx hybridoma NQ10.12.5 linked to a human Ck1 segment cloned into fdDOG-2lox as an Apa LI-Asc I  
30 fragment. Acceptor phage A also contains a VH segment from an anti-Tumour Necrosis Factor antibody (Rathjen, D.A., Furphy, L.J. and Aston, R. (1992) Br. J. Cancer, 65, 852-856.) linked to a human Cm1 segment, and cloned into fdDOG-2lox as an Sfi 1-Not 1 fragment.

Both A and B constructs were transformed into



E.coli TGl, construct A conferring resistance to tetracyclin, construct B conferring resistance to ampicillin.

5 (b) Preparation of infectious acceptor phage particles (construct A).

Phage particles were harvested from the medium of construct B clones grown overnight in 2x YT containing tetracycline, as described in PCT WO 92/01047, example

10 6.

(c) In vivo Cre-catalysed recombination.

This was performed as follows:

1. E. coli containing the plasmid pUC19-2lox were  
15 grown, shaking at 37°C in 2 ml 2xTY medium with 100 mg/ml ampicillin and 1% glucose to an O.D.600nm of 0.4.
2.  $5 \times 10^9$  transducing units (tu) fdDOG-2lox phage were added (a ten-fold excess over bacteria) and incubation  
20 continued at 37°C without shaking for 30 min.
3.  $5 \times 10^9$  pfu phage PlCm cl.100 (confer chloramphenicol resistance; Rosner, J.L. (1972) et. supra.) were added and incubation continued for a further 30 min. at 37°C. 40 ml of this culture were  
25 then added to 2 ml 2 xTY, 100 mg/ml ampicillin, 12.5 mg/ml tetracycline, 12.5 mg/ml chloramphenicol, 1% glucose. The culture was shaken for 40 hours at 30°C.
4. About  $10^{10}$  tu phage fd particles (including recombinant phage) were harvested from the culture  
30 supernatant by centrifuging out bacteria at 13000 g for 5 min. and passing the supernatant through a 0.45 mm sterile filter (Minisart, Sartorius).

In order to sample the recombined population,  $10^3$  tu

- of the above fd particles were infected into fresh E.coli TG1 and plated on 2 xTY agar containing 12.5 mg/ml tetracycline then incubated at 37°C overnight. Ninety six well seperated colonies were transferred to a
- 5 96 well microtitre tray containing 100ml/well 2xTY containing 12.5 mg/ml tetracycline and grown at 37°C overnight. This plate was used as a master stock which was then screened by several techniques to identify which recombination events had occurred:
- 10 (1) ELISA, to identify clones producing phage that bind to phOx-BSA (to identify vector E).  
(2) Replica plating, to find clones resisitant to both ampicillin and tetracycline (to identify vectors C and D).
- 15 (3) Colony hybridisation, with a radiolabelled oligonucleotide VHNQ10PR which binds specifically to CDR3 of NQ10.12.5 VH (to identify vectors C, D and E).  
(4) PCR, with oligonucleotides FDPCRBAC and VHNQ10PR (to identify vectors C and E).
- 20 (5) PCR, with oligonucleotides LMB3 and VHNQ10PR (to identify vector D).

(d) ELISA to identify phOX binders (vector E)

- 25 1. Coat plate (Falcon 3912) with 100 µl of phOX-BSA (14:1 substitution) per well at 10 µg/ml, in PBS. Leave overnight at room temp.
2. Rinse wells 3x with PBS, and block with 200 µl per well of 2% Marvel/PBS, for 2hs at 37°C.
- 30 3. Rinse wells 3x with PBS, then add 25 µl 10% Marvel/PBS to all wells.
4. Add 100 µl culture supernatant to the appropriate wells. Mix, leave 2 hrs room temp.
5. Wash out wells 3. times with PBS, 0.05% Tween 20 and

- 3 times with PBS. Add 100ml sheep anti-M13 antiserum diluted 1:1000 in 2% Marvel/PBS into each well. Incubate at room temp. for 1.5 hrs.
6. Wash out wells with 3 times with PBS, 0.05% Tween 20 and 3 times with PBS. Pipette 100  $\mu$ l of 1:5000 dilution of anti-sheep IgG antibody (peroxidase-conjugated, Sigma). Incubate at room temp. for 1.5 hrs.
7. Discard 2nd antibody, and wash wells 3 times with PBS, 0.05% Tween 20 and 3 times with PBS.
8. Add one 10 mg ABTS (2,2'-azino bis (3-ethylbenzthiazoline -6-sulphonic acid), diammonium salt) tablet to 20 ml 50 mM citrate buffer, pH4.5. (50 mM citrate buffer, pH4.5 is made by mixing equal volumes 50 mM trisodium citrate and 50 mM citric acid).
9. Add 20  $\mu$ l 30% hydrogen peroxide to the above solution immediately before dispensing.
10. Add 100  $\mu$ l of the above solution to each well. Leave room temp. 30 min.
11. Quench by adding 50  $\mu$ l 3.2 mg/ml sodium fluoride. Read at 405 nm.

Note 1 : 'Marvel' is dried milk powder. PBS is 5.84 g NaCl, 4.72 g  $\text{Na}_2\text{HPO}_4$  and 2.64 g  $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$ , pH 7.2, in 1 litre.

68 of the 96 clones were found to be positive in the ELISA (O.D. 405nm >1.0); 71% of the tetracycline resistant clones therefore correspond to vector E (fig.) since they encode functional anti-phOX Fab fragments on phage.

(e) Replica plating to identify vectors C and D.

Cells from the master plate were inoculated onto a

2xYT agar plate containing 100 mg/ml ampicillin, 12.5 mg/ml tetracycline and 1% glucose, using a 96 pin device. The plate was incubated at 37°C overnight. Five colonies had grown up the next day indicating that 5/96 clones had the structures shown in C or D.

(f) Colony hybridisation to identify vectors C, D and E.

Colony hybridisation was performed with the array using standard techniques as described in Sambrook et al. (1989, supra.). The probe used was a radiolabelled oligonucleotide VHNQ10PR which binds specifically to CDR3 of NQ10.12.5 VH.

73 of the 96 colonies were positive and therefore correspond to vectors C, D or E.

15

(g) PCR screening to identify vectors C and E.

PCR reactions were performed essentially as described in example 11, WO 92/01047. Cells from each of the 96 clones were carefully transferred using a toothpick into 20ml sterile water in a 0.5ml centrifuge tube. The samples were then placed in a boiling water bath for 5 minutes and 2ml of this used as template for each 20ml PCR reaction.

Thirty cycles of amplification were performed each of 94°C 1 minute, 50°C 1 minute and 72°C 2 minutes, using primers FDPCRBAC and VHNQ10PR. PCR reaction products were resolved on 1% TAE agarose gels (Sambrook et al. (1989) supra.).

72 of the 96 clones clones gave a ca. 1Kb PCR fragment and were thus scored as positive. These clones correspond to vectors C and E.

30

(g) PCR screening to identify vector D.

A second set of PCR reactions were performed on

cells from the array as described above, this time using primers LMB3 and VHNQ10PR.

Only 1 of the 96 clones gave a ca. 400bp PCR fragment and was thus scored as vector D.

5

(h) Analysis of recombinants.

The preceding experiments show that of the 96 tetracycline resistant clones that were sampled, 23 were vector A, 4 vector C, 1 vector D and 68 vector E. All 68 vector E clones produced phage which bound to phOx-BSA, but the remaining 28 clones did not (as expected). Thus, 70% of all tetracycline resistant clones corresponded to vector E, which encodes functional anti-phOx Fabs for display on phage. The process is very efficient, and should allow the creation and use of extremely large combinatorial repertoires.

Example 2. Creation of an extremely large combinatorial library using in vivo recombination.

This example describes construction of an extremely large library of V-genes from unimmunised donors, using the in vivo recombination strategy outlined in the previous example. Many of the procedures detailed below have been previously described (Marks, J et al. (1991) et supra.).

(a) Preparation of cDNA template

500 ml of blood, containing approximately  $10^8$  B-lymphocytes, was obtained from 2 healthy volunteers. The white cells were separated on Ficoll and RNA was prepared using a modified method (Cathala, G., J. Savouret, B. Mendez, B. L. Wesr, M. Karin, J. A. Martial

and J. D. Baxter. (1983). A method for isolation of intact, transcriptionally active ribonucleic acid. DNA. 2, 329.). Three first strand cDNA syntheses were made as described by Marks et al (1991, supra.) from RNA  
5 corresponding to  $2.5 \times 10^7$  B-cells, using HuIgMFOR constant region primer for the heavy chains, and HuCKFORCYS for kappa light chains and HuCLFORCYS for lambda light chains (Table 1)

10 (b) PCR of heavy chains and construction of heavy chain repertoire.

VH genes were PCR-amplified using the HuIgMFOR primer in conjunction with each of the HuVHBACK primers individually. Six separate PCR amplifications were  
15 performed each of 50  $\mu$ l reaction volume containing 5  $\mu$ l of the supernatant from the cDNA synthesis using the HUIGMFOR primer, 20 pmol total concentration of the BACK primers, 20 pmol concentration of the FORWARD primer, 250  $\mu$ M dNTPs, 10mM KCl, 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 20 mM Tris.HCl  
20 (pH 8.8), 2.0 mM MgCl<sub>2</sub>, 100 mg/ml BSA and 1  $\mu$ l (1 unit) Vent DNA polymerase (New England Biolabs). The reaction mixture was overlaid with mineral (paraffin) oil and subjected to 30 cycles of amplification using a Techne  
PHC-2 thermal cycler. The cycle was 94°C for 1 minute  
25 (denaturation), 57°C for 1 minute (annealing) and 72°C for 2.5 minutes (extension). The products were purified on a 1.0% agarose gel, isolated from the gel by GeneClean (Bio-101) and resuspended in 25  $\mu$ l of H<sub>2</sub>O. The six products were then pooled and 'pullthrough' PCR  
30 reactions performed to attach Sfi I and Not I restriction sites.

Pullthrough reactions were set up with the primers HUVHBACKSfi (equimolar mix of all 6 primers) and HUCMIFONO. 50  $\mu$ l reactions of containing 5  $\mu$ l of the

pooled PCR products from the previous step were amplified using the same conditions as for the primary PCR except that 25 cycles of amplification were used. The resulting fragments were digested with Sfi I and Not I, gel-purified, and the fragments ligated to Sfi I and Not I -cut pUC19-2lox using previously described procedures (Sambrook, J. et al. (1989) et supra; PCT WO 92/01047). The ligation mixes were phenol-chloroform extracted prior to electroporation into TG1 cells (Marks, J et al. (1991) et supra.). Briefly, the ligated DNA was resuspended in 20 µl of water, and 2.5 µl samples were electroporated into 50 µl aliquots of electro-competent E.coli TG1. Cells were grown in SOC for 1 hr and then plated on 2YT agar with 100 µg/ml ampicillin and 1% glucose (2YTAG) in 243 x 243 mm dishes (Nunc) then grown overnight at 30°C. Colonies were scraped off the plates into 2YTAG containing 15% glycerol for storage at -70°C as library stocks.

The heavy chain repertoire was calculated to have ca.  $1.10^7$  independant recombinants, which by Bst NI fingerprinting was shown to be extremely diverse (PCT WO 92/01047).

(c) PCR of Light chains and construction of kappa and lambda-chain repertoires.

Kappa and lambda-chain genes were amplified separately. Kappa chain genes were amplified using an equimolar mixture of the 12 SYNKB primers in conjunction with HuCKFORCYS (Table 1). 1-chain genes were amplified from the cDNA synthesis using an equimolar mix of the 8 DPVL primers in conjunction with the HUCLFORCYS primer. In each case 50 µl reaction mixtures were prepared containing 5 µl of the supernatant from the appropriate cDNA synthesis, 20 pmol total concentration of the BACK

primers, 20 pmol concentration of the FORWARD primers, 250  $\mu$ M dNTPs, 10mM KCl, 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 20 mM Tris.HCl (pH 8.8), 2.0 mM MgCl<sub>2</sub>, 100 mg/ml BSA and 1  $\mu$ l (1 unit) Vent DNA polymerase (New England Biolabs). The reaction mixture was overlaid with mineral (paraffin) oil and subjected to 30 cycles of amplification using a Techne thermal cycler. The cycle was 94°C for 1 minute (denaturation), 57°C for 1 minute (annealing) and 72°C for 2.5 minutes (extension). The products were purified on a 1% agarose gel, isolated from the gel by GeneClean (Bio-101) and resuspended in 25  $\mu$ l of H<sub>2</sub>O.

Pullthrough reactions were now performed on each of the two light chain preparations. kappa-chain genes were amplified using an equimolar mixture of the 12 SYNKBapa primers in conjunction with either HUCKFORCYSNOT. lambda-chain genes were amplified using an equimolar mixture of the 8 DPVLapa primers in conjunction with HUCKFORCYSNOT. Pullthrough conditions were performed as for the primary light chain PCRs above except that 25 cycles of amplification were used.

Kappa and lambda-chain repertoires were processed separately. In each case, PCR products were digested with Apa LI and Not I and ligated into Apa LI-Not I-cut fdDOG-2lox (prepared using the standard format), the ligation mixes were purified by phenol extraction and ethanol precipitated prior to electroporation into TG1 as above, except that transformed cells were plated on 2YT agar with 12.5  $\mu$ g/ml tetracycline in 243 x 243 mm dishes (Nunc) then grown overnight at 30°C. Colonies were scraped off the plates into 2YT containing 15% glycerol for storage at -70°C as library stocks.

The kappa and lambda-chain repertoires were calculated to have ca.  $1.10^6$  independent recombinants; again, Bst NI fingerprinting indicates that both



libraries were extremely diverse.

(d) In vivo recombination of heavy and light chains.

The kappa and lambda-chain repertoires were  
5 separately recombined with the heavy chain repertoire  
using a scale-up of the procedure described in example  
1.

O.D.600nm was used to calculate the cell density of  
the stocks scraped from the plates, using the algorithm  
10 O.D.600nm of 1.0 =  $5 \cdot 10^8$  cells. Approximately  $1 \cdot 10^{10}$   
cells from each of the kappa and lambda-chain  
repertoires in fdDOG-2lox were inoculated into 1 litre  
volumes of 2xYT containing 12.5 µg/ml tetracycline and  
grown for 30hrs at 37 C with rapid shaking. Phage  
15 particles were harvested from the clarified growth  
medium as described in PCT WO 92/01047, example 6, and  
stocks adjusted to ca.  $1 \cdot 10^{12}$  TU ml<sup>-1</sup>.

$1 \cdot 10^{11}$  cells from the heavy chain repertoire were  
inoculated into 2x 1 litre volumes 2YTAG in 2.5L shake  
20 flasks and grown at 37 C with rapid shaking until the  
cultures reached an O.D.<sub>600nm</sub> of 0.4 ml<sup>-1</sup>.  $5 \cdot 10^{12}$  fdDOG-2lox  
kappa and lambda fdDOG-2lox phage were added (a ten-fold  
excess over bacteria) and incubation continued at 37°C  
without shaking for 30 min.  $5 \cdot 10^{12}$  pfu phage PlCm cl.100  
25 were then added and incubation continued for a further  
30 min. at 37°C. The cultures were then centrifuged at  
4,000x g for 15 minutes at 4°C and the supernatant  
poured off. The cell pellets were resuspended in 1litre  
of 2 xTY, 100 mg/ml ampicillin, 12.5 mg/ml tetracycline,  
30 12.5 mg/ml chloramphenicol, 1% glucose and the cultures  
shaken for 40 hours at 30°C. Phage fd particles  
(including recombinant phage) were harvested from the  
culture supernatant by centrifuging out bacteria at  
13000 g for 15minutes and the particles PEG

precipitated.

The recombined library phage were then resuspended in 10mM TRIS-HCl (pH 8.0), 1mM EDTA and adjusted to  $1.10^{12}$  TU ml<sup>-1</sup>: this stock represents the library.

- 5 These phage are selected on antigen, reinfected into fresh E.coli and recovered by plating on 2x YT agar containing 12.5 µg/ml tetracycline. Growth of selected phages is achieved by culture in 2x YT containing 12.5 µg/ml tetracycline (no other antibiotics necessary- see
- 10 fig 4, construct E), and phages bearing functional antibodies recovered from the growth medium.

Note: Sbp members and encoding nucleic acid therefor obtained using the present invention may be used in the production of derivatives. The term

15 derivative is discussed above.

TABLE 1 Oligonucleotide sequences

ALL WRITTEN 5' -&gt; 3'

**A) Primers for first strand cDNA synthesis****Human IgM Constant Region Primer**

HuIgMFOR 5' -TGG AAG AGG CAC GTT CTT TTC TTT-3'

**Human kappa Constant Region Primer**

HUCKFORCYS 5' -ACA CTC TCC CCT GTT GAA GCT CTT-3'

**Human lambda Constant Region Primer**HUCLFORCYS 5' -TGA ACA TTC TGT AGG GGC CAC TGT  
CTT-3'**B) Heavy chain primary PCR****VH Primers**

|            |                                      |
|------------|--------------------------------------|
| HuVH1aBACK | 5'-CAG GTG CAG CTG GTG CAG TCT GG-3' |
| HuVH2aBACK | 5'-CAG GTC AAC TTA AGG GAG TCT GG-3' |
| HuVH3aBACK | 5'-GAG GTG CAG CTG GTG GAG TCT GG-3' |
| HuVH4aBACK | 5'-CAG GTG CAG CTG CAG GAG TCG GG-3' |
| HuVH5aBACK | 5'-GAG GTG CAG CTG TTG CAG TCT GC-3' |
| HuVH6aBACK | 5'-CAG GTA CAG CTG CAG CAG TCA GG-3' |

**Forward Primer**

HuIgMFOR 5' -TGG AAG AGG CAC GTT CTT TTC TTT-3'

**C) Heavy chain reamplification with restriction site primers****VH Back Primers**

|               |  |
|---------------|--|
| HuVH1aBACKSfi | 5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC<br>ATG GCC CAG GTG CAG CTG GTG CAG<br>TCT GG-3' |
| HuVH2aBACKSfi | 5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC<br>ATG GCC CAG GTC AAC TTA AGG GAG<br>TCT GG-3' |
| HuVH3aBACKSfi | 5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC<br>ATG GCC GAG GTG CAG CTG GTG GAG              |

TCT GG-3'

HuVH4aBACKSf1 5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC  
ATG GCC CAG GTG CAG CTG CAG GAG  
TCG GG-3'

HuVH5aBACKSf1 5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC  
ATG GCC CAG GTG CAG CTG TTG CAG  
TCT GC-3'

HuVH6aBACKSf1 5'-GTC CTC GCA ACT GCG GCC CAG CCG GCC  
ATG GCC CAG GTA CAG CTG CAG CAG  
TCA GG-3'

## Forward primer

HCM1FONO 5' -CCA CGA TTC TGC GGC CGC CAC TGG AAG  
AGG CAC GTT CTT TTC TTT

## D) Kappa chain primary PCR

## Back primers

SYNKB1 5'-GAC ATC CAG (A/T)TG ACC CAG-3'  
SYNKB2 5'-GTC ATC TGG ATG ACC CAG-3'  
SYNKB3 5'-GCC ATC CAG ATG ACC CAG-3'  
SYNKB4 5'-GAT (A/G)TT GTG ATG ACT CAG-3'  
SYNKB5 5'-GA(T/G) ATT GTG ATG ACC CAG-3'  
SYNKB6 5'-GAA ATT GTG TTG ACG CAG-3'  
SYNKB7 5'-GAA ATA GTG ATG ACG CAG-3'  
SYNKB8 5'-GAC ATC GTG ATG ACC CAG-3'  
SYNKB9 5'-CAG CAG GGC AAT AAG CAC-3'  
SYNKB10 5'-CAT CAG AGT AGT AGT TTA C-3'  
SYNKB11 5'-AAC ATC CAG ATG ACC CAG-3'  
SYNKB12 5'-GAA ATT GTA ATG ACA CAG-3'

## Forward Primer

HUCKFORCYS see above

## E) Kappa chain reamplification with primers containing restriction sites

## Back primers

SYNKB1Apa 5'-CAT GAC CAC AGT GCA CTT GAC ATC CAG  
(A/T)TG ACC CAG-3'  
SYNKB2Apa 5'-CAT GAC CAC AGT GCA CTT GTC ATC TGG ATG  
ACC CAG-3'  
SYNKB3Apa 5'-CAT GAC CAC AGT GCA CTT GCC ATC CAG ATG  
ACC CAG-3'  
SYNKB4Apa 5'-CAT GAC CAC AGT GCA CTT GAT (A/G)TT GTG  
ATG ACT CAG-3'  
SYNKB5Apa 5'-CAT GAC CAC AGT GCA CTT GA(T/G) ATT GTG

59

ATG ACC CAG-3'  
 SYNKB6Apa 5'-CAT GAC CAC AGT GCA CTT GAA ATT GTG TTG  
 ACG CAG-3'  
 SYNKB7Apa 5'-CAT GAC CAC AGT GCA CTT GAA ATA GTG ATG  
 ACG CAG-3'  
 SYNKB8Apa 5'-CAT GAC CAC AGT GCA CTT GAC ATC GTG ATG  
 ACC CAG-3'  
 SYNKB9Apa 5'-CAT GAC CAC AGT GCA CTT CAG CAG GGC AAT  
 AAG CAC-3'  
 SYNKB10Apa 5'-CAT GAC CAC AGT GCA CTT CAT CAG AGT AGT  
 AGT TTA C-3'  
 SYNKB11Apa 5'-CAT GAC CAC AGT GCA CTT AAC ATC CAG ATG  
 ACC CAG-3'  
 SYNKB12Apa 5'-CAT GAC CAC AGT GCA CTT GAA ATT GTA ATG  
 ACA CAG-3'

## Forward primers

HUCKFORCYSNOT 5'-GAG TCA TTC TCG ACT TGC GGC CGC ACA  
 CTC TCC CCT GTT GAA GCT CTT-3'

## F) Lambda chain primary PCR

## Back primers

DPVL1a 5'-CAG TCT GTG (T/C)TG ACG CAG CCG CC-3'  
 DPVL1b 5'-CAG TCT GTC GTG ACG CAG CCG CC-3'  
 DPVL1c 5'-CAG TCT GTG CTG ACT CAG CCA CC-3'  
 DPVL2 5'-CA(G/A) TCT GCC CTG ACT CAG CCT-3'  
 DPVL3a 5'-TCT TCT GAG CTG ACT CAG GAC CC-3'  
 DPVL3b 5'-TCC TAT GAG CTG ACT CAG CCA CC-3'  
 DPVL7/8 5'-CAG (A/G)CT GTG GTG AC(T/C) CAG GAG  
 CC-3'  
 DPVL9 5'-C(A/T)G CCT GTG CTG ACT CAG CC(A/C)  
 CC-3'

## Forward primer

HUCLFORCYS see above

## G) Lambda chain reamplification with primers containing restriction sites

## Back primers

DPVL1aApa 5'-CAT GAC CAC AGT GCA CTT CAG TCT GTG  
 (T/C)TG ACG CAG CCG CC-3'  
 DPVL1bApa 5'-CAT GAC CAC AGT GCA CTT CAG TCT GTC GTG  
 ACG CAG CCG CC-3'

DPVL1cApa 5'-CAT GAC CAC AGT GCA CTT CAG TCT GTG CTG  
ACT CAG CCA CC-3'  
DPVL2Apa 5'-CAT GAC CAC AGT GCA CTT CA(G/A) TCT GCC  
CTG ACT CAG CCT-3'  
DPVL3aApa 5'-CAT GAC CAC AGT GCA CTT TCT TCT GAG CTG  
ACT CAG GAC CC-3'  
DPVL3bApa 5'-CAT GAC CAC AGT GCA CTT TCC TAT GAG CTG  
ACT CAG CCA CC-3'  
DPVL7/8Apa 5'-CAT GAC CAC AGT GCA CTT CAG (A/G)CT GTG  
GTG AC(T/C) CAG GAG CC-3'  
DPVL9Apa 5' -CAT GAC CAC AGT GCA CTT C(A/T)G CCT GTG  
CTG ACT CAG CC(A/C) CC-3'

#### Forward primers

HUCLFORCYSNOT 5'-GAG TCA TTC TCG ACT TGC GGC CGC TGA  
ACA TTC TGT AGG GGC CAC TGT CTT-3'

#### H) Other primers/probes

VHNQ10PR 5' -ATA AGC CCC GTA ATC TCT TGC-3  
FDPCRBAC 5' -GCB ATG GTT GTT GTC ATT GTC GGC-3  
LMB3 5' -CAG GAA ACA GCT ATG AC-3

CLAIMS

1. A method for producing multimeric specific binding pair (sbp) members, which method comprises  
5 causing or allowing recombination between (a) first vectors comprising nucleic acid encoding a population of a fusion of a first polypeptide chain of a specific binding pair member and a component of a replicable genetic display package (rgdp) and (b) second  
10 vectors comprising nucleic acid encoding a population of a second polypeptide chain of a specific binding pair member, at least one of said populations being genetically diverse, the recombination resulting in recombinant vectors each of which comprises nucleic acid  
15 encoding a said polypeptide fusion and a said second polypeptide chain and capable of being packaged into rgdps using said rgdp component.
2. A method according to claim 1 comprising  
20 expressing said polypeptide fusions and said second polypeptide chains, producing rgdps which display at their surface said first and second polypeptide chains and which each comprise nucleic acid encoding a said first polypeptide chain and a said second polypeptide  
25 chain.
3. A method according to claim 1 or claim 2 wherein the recombination is intracellular and promoted by inclusion in the vectors of sequences at which site-  
30 specific recombination will occur.
4. A method according to claim 1 or claim 2 wherein the recombination takes place in vitro and is promoted by inclusion in the vectors of sequences at which site-  
35 specific recombination will occur.
5. A method according to claim 3 or claim 4 wherein

said resultant recombinant vector comprises nucleic acid encoding a single chain sbp member resulting from recombination between first and second vectors.

5 6. A method according to any one of claims 3, 4 and 5 wherein the sequences at which site-specific recombination will occur are loxP sequences obtainable from coliphage P1 or sequences derived from such a loxP sequence, and site-specific recombination is catalysed  
10 by Cre-recombinase, obtainable from coliphage P1.

7. A method according to claim 6 wherein the Cre-recombinase used is expressible under the control of a regulatable promoter.

15

8. A method according to claim 3 or claim 4 wherein each of the first vectors and each of the second vectors includes a first site-specific recombination sequence and a second site-specific recombination sequence  
20 different from the first, site-specific recombination taking place between first site-specific recombination sequences on different vectors and between second site-specific recombination sequences on different vectors but not between a first site-specific recombination  
25 sequence and a second site-specific recombination sequence on the same vector.

9. A method according to claim 8 wherein the first site-specific recombination sequence is loxP obtainable  
30 from coliphage P1 and the second site-specific recombination sequence is a mutant loxP sequence.

10. A method according to claim 8 wherein the first site-specific recombination sequence is a loxP mutant  
35 and the second site-specific recombination sequence is loxP obtainable from coliphage P1.



11. A method according to claim 9 or claim 10 wherein the mutant loxP sequence is loxP 511.
12. A method according to claim 1 wherein the first  
5 vectors are phages or phagemids and the second vectors are plasmids, or the first vectors are plasmids and the second vectors are phages or phagemids.
13. A method according to claim 12 wherein the  
10 intracellular recombination takes place in a bacterial host which replicates the recombinant vector preferentially over the first vectors and the second vectors.
14. A method according to claim 13 wherein the  
15 intracellular recombination takes place in a bacterial host which replicates plasmids preferentially over phages or phagemids, or which replicates phages or phagemids preferentially over plasmids.  
20
15. A method according to claim 14 wherein said  
bacterial host is a PolA strain of E.coli or of another gram-negative bacterium.
16. A method according to any preceding claim wherein  
25 nucleic acid from one or more rgdp's is taken and used in a further method to obtain an individual sbp member or a mixed population of sbp members, or polypeptide chain components thereof, or encoding nucleic acid  
30 therefor.
17. A method of producing multimeric specific binding pair (sbp) members, which method comprises:  
(i) expressing from a vector in recombinant host  
35 organism cells a population of a first polypeptide chain of a specific binding pair member fused to a component of a replicable genetic display package (rgdp) which

- thereby displays said polypeptide chains at the surface of rgdps, and combining said population with a population of a second polypeptide chain of said specific binding pair member by causing or allowing
- 5 first and second polypeptide chains to come together to form a library of said multimeric specific binding pair members displayed by rgdps, said population of second polypeptide chains not being expressed from the same vector as said population of first polypeptide chains,
- 10 at least one of said populations being genetically diverse and expressed from nucleic acid that is capable of being packaged using said rgdp component, whereby the genetic material of each said rgdp encodes a polypeptide chain of a said genetically diverse population;
- 15 (ii) selecting or screening rgdps formed by said expressing to provide an individual sbp member or a mixed population of said sbp members associated in their respective rgdps with nucleic acid encoding a polypeptide chain thereof;
- 20 (iii) obtaining nucleic acid from a selected or screened rgdp, the nucleic acid obtained being one of (a) nucleic acid encoding a first polypeptide chain, (b) nucleic acid encoding a second polypeptide chain, and (c) a mixture of (a) and (b);
- 25 (iv) producing a recombinant vector by causing or allowing recombination between (a) a vector comprising nucleic acid obtained in step (iii) encoding a first polypeptide chain and a vector comprising nucleic acid encoding a second polypeptide chain, or (b) a vector
- 30 comprising nucleic acid encoding a first polypeptide chain and a vector comprising nucleic acid obtained in step (iii) encoding a second polypeptide chain.
18. A method according to claim 17 wherein the
- 35 recombination takes place in vitro.
19. A method according to claim 17 wherein the

recombination is intracellular.

20. A method according to claim 18 or claim 19 wherein the intracellular recombination is promoted by  
5 inclusion in the vectors of sequences at which site-specific recombination will occur.

21. A method according to claim 20 wherein the recombinant vector comprises nucleic acid encoding a  
10 single chain sbp member resulting from recombination between first and second vectors.

22. A method according to claim 20 or 21 wherein the sequences at which site-specific recombination will  
15 occur are loxP sequences obtainable from coliphage P1 or sequences derived from such a loxP sequence, and site-specific recombination is catalysed by Cre-recombinase, also obtainable from coliphage P1.

20 23. A method according to claim 22 wherein the Cre-recombinase used is expressible under the control of a regulatable promoter.

24. A method according to claim 17 wherein the first  
25 vectors are phages or phagemids and the second vectors are plasmids, or the first vectors are plasmids and the second vectors are phages or phagemids.

25. A method according to claim 24 wherein the  
30 intracellular recombination takes place in a bacterial host which replicates the recombinant vector preferentially over the first vectors and the second vectors.

35 26. A method according to claim 25 wherein the intracellular recombination takes place in a bacterial host which replicates plasmids preferentially over

phages or phagemids, or which replicates phages or phagemids preferentially over plasmids.

27. A method according to claim 26 wherein said  
5 bacterial host is a PolA strain of E.coli or of another gram-negative bacterium.

28. A kit for use in carrying out a method according to any one of claims 3 to 11, having:

10 (i) a first vector having a restriction site for insertion of nucleic acid encoding or a polypeptide component of an sbp member, said restriction site being in the 5' end region of the mature coding sequence of a phage capsid protein, with a secretory leader sequence  
15 upstream of said site which directs a fusion of the capsid protein and sbp polypeptide to the periplasmic space of a bacterial host; and

(ii) a second vector having a restriction site for insertion of nucleic acid encoding a second said  
20 polypeptide chain,

at least one of the vectors having an origin of replication for single-stranded bacteriophage, the vectors having sequences at which site-specific recombination will occur.

25

29. Recombinant host cells harbouring a library of first vectors each comprising nucleic acid encoding a first polypeptide chain of a sbp member fused to a component of a secretable replicable genetic display  
30 package (rgdp) and second vectors each comprising nucleic acid encoding a second polypeptide chain of a sbp member, the first vectors or the second vectors or both being capable of being packaged into rgdps using the rgdp component, and the vectors having sequences at  
35 which site-specific recombination will occur.


30. A population of rgdps each displaying at its

surface a sbp member and each containing nucleic acid which encodes a first and a second polypeptide chain of the sbp member displayed at its surface and which includes a site-specific recombination sequence.

5

31. A population of rgdps each displaying at its surface a sbp member and each containing nucleic acid which comprises a combination of (i) nucleic acid encoding a first polypeptide chain of a sbp member and
- 10 (ii) nucleic acid encoding a second polypeptide chain of a sbp member, the population containing  $10^{10}$  or more combinations of (i) and (ii)

Fig.1.




2/8

Fig. 2.

# Polycombinatorial libraries

Potential library size =  $10^{12}$









4/8


Fig.3(ii).

RESCUE M13K07



RECOMBINED Ig LIBRARY

Fig. 4A.



6/8

Fig. 4A. (Cont.)





Fig. 4B.


|   |   |   |   |
|---|---|---|---|
| <p><b>κ</b></p> <p><b>g e c</b></p> <p>GGAGAGTGTATTAAAGCGCGCGCAAGCTTCCTTAAT</p> <p>Ascl</p> <p>HindIII</p>  | <p>ATAACTTCGTATA</p> <p>ATGTATAC</p> <p>#</p> | <p>TATACGAAGTTAT</p> <p>TAGGTGCGCATGCAAAATCTTATTTCAAGGAGACAGTCATAATGAAA</p> <p>r.b.s</p>      | <p>leader</p> <p>M K</p> <p>fdDOG-2lox</p> <p>loxP 511 site</p> |
|   |   |   |   |
|   |   |   |   |
| <p><b>λ</b></p> <p><b>g e c</b></p> <p>AACAGCTATGACCATGATTACGCCAAGCTTCCTTAAT</p> <p>Ascl</p> <p>HindIII</p> | <p>ATAACTTCGTATA</p> <p>ATGTATAC</p> <p>#</p> | <p>TATACGAAGTTAT</p> <p>TAGGTGCGCATGCAAAATCTTATTTCAAGGAGACAGTCATAATGAAA</p> <p>r.b.s</p>      | <p>leader</p> <p>M K</p> <p>pUC19-2lox</p> <p>loxP 511 site</p> |
|   |   |   |   |
|   |   |   |   |
| <p><b>λ</b></p> <p><b>g e c</b></p> <p>AAAGACGGTCCCTCTTCAGTGGCGCGCCCTTAAT</p> <p>NdeI</p>                   | <p>I T S Y</p> <p>ATGTATGC</p> <p>N V C</p>   | <p>Y T K L</p> <p>TATACGAAGTTAT</p> <p>L G L A A E T V E S C L A K P H</p> <p>fd gene III</p> | <p>fdDOG-2lox</p> <p>wt loxP site</p>                           |
|   |   |   |   |
|   |   |   |   |
| <p><b>λ</b></p> <p><b>g e c</b></p> <p>GAAAGTTGACCCCAAACTTCAGCGCGCGCCCTTAAT</p> <p>NdeI</p>                 | <p>I T S Y</p> <p>ATGTATGC</p> <p>N V C</p>   | <p>Y T K L</p> <p>TATACGAAGTTAT</p> <p>L G L A A E Q K L I S E D L N</p> <p>myc Tag</p>       | <p>pUC19-2lox</p> <p>wt loxP site</p>                           |
|   |   |   |   |
|   |   |   |   |

loxP site

*Fig. 5(i).*



*Fig. 5(ii).*



|  |   |   |
|--|---|---|
| <b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>  |   |   |
| According to International Patent Classification (IPC) or to both National Classification and IPC  |   |   |
| Int.Cl. 5 C12N15/00;<br>G01N33/531;  | C12N15/13;<br>G01N33/68   | C12N15/62;<br>C07K13/00                             |
| <b>II. FIELDS SEARCHED</b>   |   |   |
| Minimum Documentation Searched <sup>7</sup>  |   |   |
| Classification System  | Classification Symbols  |   |
| Int.Cl. 5  | C12N ; C07K ; G01N  |   |
| Documentation Searched other than Minimum Documentation<br>to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>  |   |   |
| <b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>  |   |   |
| Category <sup>10</sup>   | Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>      | Relevant to Claims No. <sup>13</sup>                |
| E,X  | WO,A,9 311 236 (MEDICAL RESEARCH COUNCIL,<br>GB)<br>10 June 1993<br><br>See the claims                              | 1-5,8,<br>12-14,<br>16-21,<br>24-26,<br>28-30       |
| P,X  | WO,A,9 220 791 (CAMBRIDGE ANTIBODY<br>TECHNOLOGY LTD, GB)<br>26 November 1992<br>see the whole document<br><br>-/-- | 1-30  |
| <p><sup>10</sup> Special categories of cited documents :<sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> |   |   |
| <b>IV. CERTIFICATION</b>   |   |   |
| Date of the Actual Completion of the International Search  |   | Date of Mailing of this International Search Report |
| 07 JULY 1993   |   | 21. 07. 93  |
| International Searching Authority  |   | Signature of Authorized Officer                     |
| EUROPEAN PATENT OFFICE   |   | NAUCHE S.A.   |

| III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET) |  |   |
|--|--|---|
| Category *   | Citation of Document, with indication, where appropriate, of the relevant passages   | Relevant to Claim No.                         |
| X  | WO,A,9 201 047 (CAMBRIDGE ANTIBODY TECHNOLOGY LTD, GB)<br>23 January 1992<br>cited in the application  | 1-5,8,<br>12-14,<br>16-21,<br>24-26,<br>28-30 |
| Y  | See the claims   | 6,7,<br>9-11,15,<br>22,23,27                  |
| Y  | ---<br>WO,A,9 102 801 (DU PONT DE NEMOURS AND CO., US)<br>7 March 1991<br>See the claims   | 6,7,<br>9-11,15,<br>22,23,27                  |
| Y  | ---<br>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA.<br>vol. 87, January 1990, WASHINGTON US<br>pages 103 - 107<br>Stenberg, N.; 'Bacteriophage P1 cloning system for the isolation, amplification and recovery of DNA fragments as large as 100 kilobase pairs.'<br>see the whole document<br>----- | 6,7,<br>9-11,15,<br>22,23,27                  |

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9300605  
SA 71798

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07/07/93

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) |         | Publication<br>date |
|---|---------------------|----------------------------|---------|---------------------|
| WO-A-9311236                              | 10-06-93            | AU-A-                      | 1693892 | 30-12-92            |
|   |                     | WO-A-                      | 9220791 | 26-11-92            |
|   |                     | WO-A-                      | 9306213 | 01-04-93            |
| -----                                     |                     |                            |         |                     |
| WO-A-9220791                              | 26-11-92            | AU-A-                      | 8221691 | 04-02-92            |
|   |                     | WO-A-                      | 9201047 | 23-01-92            |
|   |                     | AU-A-                      | 1693892 | 30-12-92            |
|   |                     | WO-A-                      | 9306213 | 01-04-93            |
|   |                     | WO-A-                      | 9311236 | 10-06-93            |
| -----                                     |                     |                            |         |                     |
| WO-A-9201047                              | 23-01-92            | AU-A-                      | 8221691 | 04-02-92            |
|   |                     | WO-A-                      | 9220791 | 26-11-92            |
|   |                     | AU-A-                      | 1693892 | 30-12-92            |
| -----                                     |                     |                            |         |                     |
| WO-A-9102801                              | 07-03-91            | EP-A-                      | 0489002 | 10-06-92            |
| -----                                     |                     |                            |         |                     |



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**